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Abstract 
TRPM6 and TRPM7 are bifunctional proteins containing an ion channel segment 
covalently linked to a kinase domain. Both proteins function as divalent cation-selective 
channels highly permeable to Mg2+ and Ca2+, whose activity is regulated by intracellular 
levels of Mg2+ and Mg·ATP. TRPM7 has been found in all mammalian cells 
investigated so far, while expression of TRPM6 is restricted to epithelial cells of the 
kidney, intestine and placenta. TRPM6 and TRPM7 have been proposed to be required 
for cellular Mg2+ homeostasis. However, the exact role of TRPM7 in the regulation of 
Mg2+ metabolism remains poorly understood and discussed controversially. Loss-of-
function mutations in the human TRPM6 gene give rise to an autosomal recessive 
disorder called hypomagnesemia with secondary hypocalcemia (HSH). It has been 
suggested that in epithelial cells TRPM6 functions primarily as a constituent of 
heteromeric TRPM6/M7 channel complexes, but this concept has not been thoroughly 
examined. Therefore, the main goal of this work was to define the cellular function of 
TRPM6 and TRPM7 in cells either expressing only TRPM7 or co-expressing both 
proteins, TRPM6 and TRPM7. In the first line of our experiments, we generated and 
functionally characterized three different cell lines deficient in TRPM7 such as mouse 
trophoblast stem (TS) cells, human haploid leukaemia (HAP1) cells and primary 
isolated mouse megakaryocytes (MKs). Using the patch-clamp approach, we showed 
that all three cell lines lacked endogenous TRPM7 divalent cation-selective currents. 
We also found that TRPM7 deficient TS and HAP1 cells developed Mg2+ deficiency and 
growth arrest, which could be rescued by increased levels of Mg2+ in the culture 
medium. TRPM7 deficient MKs were viable but exhibited reduced Mg2+ contents and 
impaired proplatelet formation. Similar to TS and HAP1 cells, the changes in MKs were 
reversed by Mg2+ supplementation. We concluded that the TRPM7 channel controls the 
cellular Mg2+ uptake necessary for the cell proliferation. To get insights into the cellular 
role of the native TRPM6 protein, we generated TRPM6 deficient TS cells. We 
observed that, in contrast to TRPM7 KO TS cells, TRPM6 deficient TS cells were able 
to proliferate in a medium not fortified by additional Mg2+. Furthermore, the currents in 
TRPM6 KO TS cells were reduced and more sensitive to cytosolic Mg·ATP compared 
to the WT TS cells. These findings are in line with the notion that endogenous TRPM6 
functions as a subunit of heteromeric TRPM6/M7 channel complexes, where TRPM6 
potentiate Mg2+ currents due to offset of the inhibitory effect of Mg·ATP. Our 
experiments with the endogenous TRPM6 and TRPM7 channels were further verified 
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using recombinant TRPM6 and TRPM7 proteins overexpressed in HEK 293 cells. We 
observed that the recombinant TRPM6 and TRPM7 channels contribute differently to 
the functional characteristics of the heteromeric TRPM6/M7 channels mimicking the 
situation with TS cells lacking endogenous TRPM6. Most remarkably, we found that 
association of TRPM6 with TRPM7 results in large TRPM6/M7 currents insensitive to 
cytosolic levels of Mg·ATP. Taken together, we conclude that ubiquitously expressed 
TRPM7 is required for the cellular uptake of Mg2+ and that this function cannot be 
compensated by TRPM6. Association of TRPM6 in heteromeric TRPM6/M7 channel 
complexes allows to maintain a high rate of Mg2+ uptake in transporting epithelial cells.  
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Abbreviations 
2-APB   2-aminoethyl diphenylborinate 
Ab   antibody 
APS   ammonium peroxydisulphate 
ATP   adenosine triphosphate 
BAPTA   1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
bp   base pair 
BSA   bovine serum albumin 
CC   coiled-coil (domain) 
cDNA   complementary DNA 
DCT   distal convoluted tubule 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
dNTP   deoxyribonucleotide triphosphates 
DPBS   Dulbecco’s phosphate buffered saline 
DTT   dithiothreitol 
DVF   divalent cation-free solution 
ECL   enhanced chemiluminescence 
EDTA   ethylenediaminetetraacetic acid 
EGFP   enhanced green fluorescent protein 
EGTA   ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
FBS   fetal bovine serum 
FGF4   fibroblast growth factor 4 
Fwd   forward 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
HAP1 cells  human leukemia haploid cells 
HEPES   4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HEK 293 cells  human embryonic kidney 293 cells 
HPR   horseradish peroxidase 
HSH   hypomagnesemia with secondary hypocalcemia 
IC50   half-maximal inhibitory concentration 
IgG   immunoglobulin G 
IMDM   Iscove's modified Dulbecco's medium 
IP   immunoprecipitation 
IRES   internal ribosome entry site 
ISH   in situ hybridization 
I-V   current-voltage relationship 
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KO   knockout 
MEM   Eagle´s minimum essential medium 
MagNum  magnesium nucleotide-regulated metal ion currents 
MIC   Mg
2+
-inhibited cation currents 
MKs   mekacaryocytes 
mRNA   messenger RNA 
n.f.   nominally free 
NMDG   N-methyl-D-glucamine 
NEAA   non-essential amino acids 
NeoR   neomycin resistance cassette 
NTD   neural tube defect 
PCR   polymerase chain reaction 
Pf4   platelet factor 4 
PIP2   phosphatidylinositol 4,5-bisphosphate 
PMEF   primary mouse embryonic fibroblasts 
Rev   revers 
RNA   ribonucleic acid 
RPMI   Roswell Park Memorial Institute medium 
Rs   series resistance 
RT-PCR  reverse transcription-polymerase chain reaction 
SDS   sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEM   standard error of the mean 
SP   splice acceptor site sequence   
TAE   tris-acetate-EDTA 
Taq   DNA-polymerase from Thermus aquaticus 
TBS   tris-buffered saline 
TBST   tris-buffered saline with Tween 20 
TGF-β1  transforming growth factor beta 1 
TGM   tris-glycine-methanol 
TGS   tris-glycine-SDS 
Thpo   thrombopoietin  
TMs   transmembrane segments 
TRP   transient receptor potential channels 
TRPM6   transient receptor potential melastatin 6 channel 
TRPM7   transient receptor potential melastatin 7 channel 
TS cells  trophoblast stem cells 
UTR   untranslated region 
WT   wild type 
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1. Introduction 
1.1. TRP channel superfamily 
The transient receptor potential (TRP) gene family represents a noteworthy group of 
ion channels with a high variety in physiological functions, ion selectivity and activation 
mechanisms [1]. Nevertheless, TRP channels also display common characteristics. All 
TRP proteins comprise six transmembrane segments and are permeable to cations [1]. 
A common feature among TRP channels is their importance in sensory physiology. 
Generally, TRP proteins play essential roles in the organismal responses to a wide 
range of external stimuli, including temperature, sound, light, touch and chemicals [1]. 
The mammalian TRP protein family, with its 28 members, is broadly expressed in the 
nervous system and in non-excitable cells [2, 3]. TRP proteins exist in a diversity of 
eukaryotic organisms including humans, mice, zebrafish, fruit flies, worms and yeast 
[1]. 
 
1.1.1. Phylogenetic groups of TRP channels 
The TRP superfamily includes an increasing number of cation channel proteins 
characterized by their homology to the Drosophila TRP channel, the founding member 
of this superfamily [1, 4]. On the basis of primary amino acid sequence identity, the 
superfamily has been divided into two groups (group 1 and 2), which are subdivided 
into seven subfamilies (Fig. 1.1). Group 1 comprises TRPC (Canonical), TRPV 
(Vanilloid), TRPM (Melastatin), TRPA (Ankyrin) and TRPN (no mechanoreceptor 
potential C, NOMPC). Group 2 contains TRPP (Polycystin) and TRPML (Mucolipin) [1, 
5]. The eighth subfamily, TRPY, comprises yeast TRP proteins [1]. 
TRP channels contain six putative transmembrane segments (6 TMs), cytosolic amino- 
(N-) and carboxy- (C-) termini, and a short hydrophobic stretch located between TM5 
and TM6 forming the channel pore [4, 6]. Similar to other 6 TMs channels, TRP 
channels exist in the form of either homo- or hetero-multimers of four TRP subunits [6-
8]. The structure of seven TRP channels (TRPV1, TRPV2, TRPV6, TRPP2, TRPA1, 
TRPC3, and Drosophila NOMPC) has been recently determined by cryo-electron 
microscopy [9-19]. Overall, these experiments confirmed the initial hypothesis that TRP 
proteins form tetramers and have a pore-forming segment located between TM5 and 
TM6. 
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Figure 1.1. Phylogenetic tree of the TRP gene family. The dendrogram includes all human 
TRP subfamilies (black text), mouse TRPC2, and zebrafish TRPN1. Moreover, one C. elegans 
and one Drosophila member of each subfamily are shown. Figure taken from [1]. 
 
Apart from TRPM channels, TRP proteins in group 1 possess multiple N-terminal 
ankyrin repeats. Ankyrin repeats are 33-residue domains, which are usually involved in 
protein-protein interactions [1, 6, 20]. The next highly conserved structural feature of 
TRPC, TRPM, and TRPN (except for NOMPC) channels is the presence of a TRP 
domain, which consists of 23-25 residues immediately C-terminal to TM6 [5]. The most 
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conserved segment of the TRP domain is the TRP box 1 motif composing only 6 amino 
acids (EWKFAR in TRPC channels) [1, 2, 21]. Another characteristic region present in 
TRPM and TRPC channels is the so-called coiled-coil (CC) domain, supposed to play a 
role in channel assembly and trafficking [22-25] (Fig. 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. The seven TRP subfamilies. Representative members from each of the TRP 
subfamilies are illustrated. Transmembrane segments (red tubes), N- and C-termini, and a pore 
loop (P) located between TM5 and TM6 are commonly present in all TRP proteins. Uncommon 
domains are also present in some groups: coiled-coil domain (CC), ankyrin repeats (A), TRP 
domain and protein kinase domain (present only in TRPM6/7). Figure taken from [5]. 
 
1.1.1.1. Group 1 TRP subfamilies 
The TRPC subfamily. The first identified members of TRP channels were named 
“canonical” or “classical” TRPs and were included in the TRPC subfamily [5]. 
Drosophila TRP, the founding member of this subfamily, was the first discovered TRP 
channel [26]. Three known Drosophila TRP channels are required for maintaining the 
light responses of photoreceptor cells [26-28]. trp gene mutations cause the response 
to light to be transient associated with a ~10-fold decrease in the level of light-induced 
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calcium (Ca2+) influx in photoreceptor cells [29]. In mammals, seven TRPC proteins 
have been identified, distributed into four groups on the basis of amino acid sequence 
similarity and functional properties: TRPC1, TRPC4/5, TRPC3/6/7 and TRPC2 [2, 30, 
31]. These channels display a large amino acid similarity to the Drosophila TRP and 
comprise three to four ankyrin repeats [2]. Mammalian TRPC proteins form non-
selective cation channels [2]. 
The TRPV subfamily. TRPV1, the archetypal mammalian TRPV member, was found 
during an expression cloning experiment aimed to produce a channel activated by 
vanilloid compounds, such as capsaicin [32]. On the basis of their amino acid 
sequence homology, ion selectivity and mechanisms of activation, mammalian TRPV 
proteins are subdivided into two groups: TRPV1–V4 and TRPV5/V6 [3]. TRPV1–V4 are 
called thermo-TRP channels, as they are activated by heat [3]. TRPV proteins contain 
three to six ankyrin repeats, lack a TRP box and display ~25% amino acid similarity 
with TRPC proteins [6]. 
The TRPM subfamily. The melastatin-related subfamily consists of eight proteins 
(TRPM1-8) in mammals, which were denominated after the first discovered member, 
melastatin or TRPM1 [1, 3, 25]. Members of this subfamily, TRPM6 and TRPM7, are 
the subject of this study, and will be described in greater details in section 1.2. 
The TRPA subfamily. The human TRPA1, the first discovered member of this 
subfamily, was found by screening for the identification of genes down-regulated after 
oncogenic transformation of human fibroblasts [1, 33]. Mammals contain only one gene 
of the subfamily, TRPA1. TRPA1 is a non-selective Ca2+-permeable channel and is 
chemically activated by several pungent compounds present in mustard oils, the 
psychoactive compound of marijuana (tetra-hydrocannabinol or THC) and bradykinin 
[34, 35]. A particular feature of TRPA proteins is the presence of high numbers of N-
terminal ankyrin repeats [5]. 
The TRPN subfamily. Several TRPN genes exist in invertebrate species (such as 
flies, worms) and non-mammalian vertebrates (fish, amphibians) [1]. Drosophila 
NOMPC (no mechanoreceptor potential C), the founding member of the subfamily, is 
involved in mechanosensory transduction [5, 36]. TRPN members contain 29 ankyrin 
repeats N-terminal to TM6 and exhibit ~20% amino acid sequence similarity with TRPC 
proteins [1]. 
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1.1.1.2. Group 2 TRP subfamilies 
TRP proteins from the group 2 display a relatively high homology to each other, but a 
low primary amino acid sequence identity to the group 1 TRP channels [5]. Unlike other 
TRP channels, the group 2 proteins contain an extensive extracellular loop between 
TM1 and TM2 [5]. Nevertheless, the members of the group 2 contain a channel 
segment comprising six TMs [5]. 
The TRPP subfamily. The archetypal TRPP channel is TRPP2 (polycystin-2 or PKD2) 
[1]. Mutations in the human PKD2 underline the autosomal dominant polycystic kidney 
disease (ADPKD) [37]. Additionally to PKD2, this subfamily contains two other 
mammalian channels, named TRPP3 (PKD2L1, polycystin-L, PCL) [38, 39] and TRPP5 
(PKD2L2) [40, 41]. TRPP proteins are Ca2+-permeable ion channels, which display 
~25% amino acid sequence similarity with TRPC proteins [5]. TRPP2 proteins lack 
ankyrin repeats and the TRP domain [2]. 
The TRPML subfamily. The TRPML subfamily was found by a discovery of the human 
TRPML1 channel (mucolipidin1; ML1) [5]. Mutations in the human TRPML1 gene are 
associated with a lysosomal storage disorder (mucolipidosis type IV) [42-44]. Besides 
TRPML1, two other closely related subfamily members, TRPML2 and TRPML3, exist in 
mammals [5]. The mammalian TRPML proteins show a very limited sequence 
homology to TRPC proteins [5]. 
 
1.2. Melastatin-related TRP (TRPM) channels 
The mammalian members from the TRPM subfamily exhibit ∼20% primary amino acid 
sequence similarity with TRPC proteins and, similar to TRPCs, they possess a TRP 
domain placed C-terminal to TM6 [1, 2]. Sequence comparison of the channel pore-
forming segment (TM5-TM6) reveals that the pore-forming sequence is highly 
conserved among all proteins of the TRPM subfamily [4]. TRPM proteins are devoid of 
ankyrin repeats and their N-terminal domain is substantially longer than the analogous 
region in TRPV and TRPC channels [2]. The TRPM subfamily contains eight members 
subdivided into five groups: TRPM1/3, TRPM4/5, and TRPM6/7; TRPM2 and TRPM8 
display a very low amino acid sequence identity and thus represent independent 
groups [3]. TRPM2, TRPM6, and TRPM7 possess the particular feature to contain 
enzymatically active proteins fused to their ion channel segments (therefore entitled as 
chanzymes) [1, 3]. 
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The first mammalian member of the TRPM subfamily, TRPM1 (or melastatin), was 
identified as a putative melanoma marker [1]. Duncan et al. demonstrated an inverse 
correlation between the expression levels of this protein and the metastatic potential in 
human melanoma cell lines [45]. Besides the full-length clone (TRPM1-L), a short 
isoform of TRPM1 (TRPM1-S) lacking predicted transmembrane segments was cloned 
[1]. TRPM1-S was shown to interact and inhibit TRPM1-L trafficking to the plasma 
membrane [46]. Functional properties of the TRPM1 channel remain poorly 
understood. Its closest relative protein, TRPM3, is mainly expressed in human kidney 
and brain where it functions as a constitutively active Ca2+-permeable cation channel 
[47]. Currents mediated by TRPM3 are activated by heat, cell swelling and steroids like 
pregnenolone sulphate (PS) [47-50]. It has been found that various splice variants of 
TRPM3 can affect ion selectivity of the channel [51]. TRPM3 functions as a 
thermosensitive nociceptor channel implicated in the noxious heat detection [48, 50]. 
Recent reports showed that the TRPM3 channel is inhibited by agonists of G protein-
coupled receptors like µ-opioid, GABA-B and neuropeptide Y receptors [52-55]. This 
inhibition occurs through direct binding of the Gβγ subunits to the TRPM3 channel [52-
55]. 
TRPM4 [56] and TRPM5 [57] are uncommon TRP channels as they are Ca2+-activated, 
voltage-modulated and monovalent cation-selective channels. At physiological 
conditions, these channels are activated by G protein-coupled receptors linked to 
phospholipase C (PLC) induced Ca2+ raises [56, 57]. TRPM4 has two splice variants, 
one of which (TRPM4a) displays very low (if any) channel activity, whereas the second 
(TRPM4b) is a highly active splice variant [56]. TRPM5 is expressed in chemosensory 
cells, such as the taste receptor cells [58], where it is required for bitter, sweet, and 
umami taste sensations [59]. 
TRPM2 is a chanzyme containing a C-terminal ADP-ribose pyrophosphatase domain 
[60, 61]. This protein functions as a Ca2+-permeable cation channel, and is activated by 
intracellular pyrimidine nucleotides, ADP-ribose and nicotinamide adenine dinucleotide 
(NAD) [60, 61]. TRPM2 acts as cellular redox sensor: it is activated by hydrogen 
peroxide and other reactive oxygen/nitrogen species [62, 63]. 
TRPM8 is a non-selective cation “thermoTRP” channel, which is activated by cold 
temperatures (8-28°C) and by ‘cooling’ compounds, such as eucalyptol, menthol, and 
icilin [64, 65]. TRPM8 is specifically expressed in sensory neurons functioning as cold 
sensors [64, 65]. 
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1.2.1. TRPM6 and TRPM7 kinase-coupled channels 
Among known ion channels, TRPM6 and TRPM7 are unique since they contain C-
terminal functional kinase domains [66, 67]. TRPM6 and TRPM7 are highly 
homologous channels with a global primary amino acid sequence similarity of 52%, 
which rises to >80% in the pore-forming region between TM5 and TM6 [68]. Both 
proteins were found to be linked to the regulation of cellular magnesium (Mg2+) 
homeostasis. Chicken DT40 B lymphocytes with a targeted gene deletion of TRPM7 
developed Mg2+ deficiency and underwent growth arrest [67, 69], whereas loss-of-
function mutations in the human TRPM6 gene cause an autosomal recessive disorder, 
named hypomagnesemia with secondary hypocalcemia (HSH) [70, 71]. TRPM6 is 
highly expressed in the kidney and intestine [68, 70, 71], whereas TRPM7 shows a 
ubiquitous expression profile [66, 67]. TRPM6 and TRPM7 form divalent cation-
selective channels, conducting a wide range of divalent cations including Ca2+ and 
Mg2+ [72]. TRPM6 and TRPM7 channels are regulated by intracellular Mg2+ and 
Mg·ATP [67, 68], and phosphatidylinositol 4,5-bisphosphate (PIP2) levels [73, 74]. 
TRPM7 was cloned independently by three groups. In a first group, TRPM7 was 
discovered in the effort to identify phospholipase C (PLC)-interacting proteins with 
similarity to eukaryotic elongation factor 2 kinase (eEF-2 kinase) and Dictyostelium 
myosin heavy chain kinase B (MHCK B) [66]. In a second group, TRPM7 was identified 
by screening for homologues of human eEF-2 kinase [75]. Finally, a third group cloned 
mouse and human TRPM7 aiming at identifying novel Ca2+/cation channels expressed 
in haematopoietic cells [67]. Accordingly, this protein was named TRP-PLIK (TRP-
Phospholipase C Interacting Kinase) [66], LTRPC7 (Long TRP Channel 7) [67] or 
ChaK1 (Channel-Kinase 1) [76]. 
TRPM6 was originally discovered by Ryazanova et al. in screening experiments to 
identify homologues of human eEF-2 kinase [75]. In follow-up efforts, two other groups 
showed independently that TRPM6 mutations are linked to HSH [70, 71]. TRPM6 was 
also known as TRP-PLIK2, LTRPC6 or Chak2. 
 
1.2.1.1. Expression patterns of TRPM6 and TRPM7  
The human TRPM7 gene is located on chromosome 15q21.2 (NCBI Gene ID 54822) 
and encodes a protein of 1,865 amino acids (~220 kDa). TRPM7 orthologs have been 
found in mouse (Mus musculus), chimpanzee (Pan troglodytes), rat (Rattus 
norvegicus), dog (Canis familiaris) and cow (Bos taurus) (GeneCards). TRPM7 was 
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also identified in non-mammalian genetically tractable organisms, in particular, in 
Zebrafish (Danio rerio) and Xenopus laevis [25]. 
In Homo sapiens, the TRPM6 gene is located on chromosome 9q21.13 (NCBI Gene ID 
140803) and the full-length isoform encodes a protein of 2,022 amino acids (~230 kDa) 
[71, 77, 78] (Fig. 1.3A). TRPM6 orthologs were identified in all vertebrate species, 
including Rattus norvegicus, Mus musculus and Danio rerio (GeneCards) [78]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Gene structure and domain organization of the human TRPM6 protein. (A) 
Structure of the human Trpm6 gene and mRNA. The gene includes 39 exons (numbered 1-39, 
black boxes), including three alternative first exons (1A, 1B, 1C), the 3' untranslated region 
(UTR) and the 5'UTR. Figure modified from [71, 77, 78]. (B) Domain topology of TRPM6. The 
six transmembrane helices form the channel segment of TRPM6, with a pore-forming loop 
between TM5 and TM6. The intracellular C-terminal of TRPM6 contains the kinase domain. The 
TRP and coiled-coil (CC) domains are also illustrated. The position of two missense mutations 
found in HSH patients [77, 79] are represented with red dots. Figure modified from [78]. 
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Initial analyses of multiple mouse tissues (brain, heart, lung, spleen, liver, kidney, 
muscle and testis) by Northern blot [66] and electrophysiological investigations of 
several cell lines (HEK 293, RBL-2H3 and Jurkat T-lymphocytes) [67] revealed that 
TRPM7 is widely expressed. An extensive analysis by quantitative real-time PCR (qRT-
PCR) of human [80] and mouse [81] tissues showed a ubiquitous expression of 
TRPM7. In humans, the highest expression of TRPM7 was found in the heart, pituitary, 
bone and adipose tissue [80]. The mouse TRPM7 channel is highly expressed in the 
intestine, kidney, lung and brain [81]. 
Different studies documented the expression of TRPM6 in various tissues. RT-PCR 
analysis of rat tissues detected TRPM6 in the kidney and intestine [71]. Additional 
analysis on microdissected rat nephrons showed high expression levels of TRPM6 in 
the distal convoluted tubule (DCT), the major site of active transcellular Mg2+ 
reabsorption of the nephron [71]. In addition, TRPM6 was found to be weakly 
expressed in proximal tubule and collecting duct [71]. In situ hybridization (ISH) in 
different human tissues revealed TRPM6 transcripts in the duodenum, jejunum, ileum 
and colon as well as in DCT segments of the kidney [71]. By Northern blot analysis, 
TRPM6 expression was detected in the human kidney, colon, and lung and testis [70]. 
Thus, TRPM6 seems to be mostly expressed in transporting epithelia of the intestine 
and kidney, but TRPM6 mRNA was also found in other tissues. 
 
1.2.1.2. Domain organization of TRPM6 and TRPM7 
In analogy to other members of the TRP superfamily, both TRPM6 and TRPM7 include 
six transmembrane helices with a putative pore-forming loop located between TM5 and 
TM6 [1, 3, 6] (Fig. 1.3B). Like other TRP channels, TRPM6 and TRPM7 are thought to 
form tetrameric channel complexes [4]. It has been proposed that TRPM6 and TRPM7 
can function as homo- as well as hetero-tetramers [6-8]. In particular, TRPM6 
assembles with TRPM7. Such interaction seems to promote the translocation of 
TRPM6 from an intracellular membrane compartment to the cell membrane [77, 82]. 
The TRP domain, located downstream of TM6 of TRPM6 and TRPM7, contains the 
conserved TRP box sequence WKYNRY in TRPM6 and WKYQRY in TRPM7 [1, 3]. 
The TRP domain is followed by the cytoplasmic CC domain, which appears to be 
involved in homo- and heterotetrameric associations of TRPM6 and TRPM7 [22, 23, 
83]. TRPM6 and TRPM7 comprise an active serine/threonine kinase domain at their C-
ends, which belongs to the atypical family of eukaryotic α-kinases [66, 67, 76, 84]. 
 
Introduction 
 
 
 
10 
 
Several α-kinases are known in mammals, including TRPM6 and TRPM7. α-Kinases 
show no obvious sequence identity to conventional eukaryotic protein kinases [76, 85]. 
Contrary to conventional protein kinases phosphorylating amino acids located within 
loops, the α-kinases phosphorylate amino acids within α-helices [84, 85]. The kinase 
domain of TRPM7 autophosphorylates its own residues [86]. Various TRPM7 kinase 
substrates were identified, including annexin I [87], myosin II (also phosphorylated by 
TRPM6 kinase) [88], eEF-2 kinase [89], and phospholipase C gamma 2 (PLCγ2) [90]. 
The physiological significance of channel kinase activity remains poorly understood. 
 
1.2.1.3. Ion permeation profiles of TRPM6 and TRPM7 channels 
Initially, TRPM7 was functionally characterized in heterologous expression systems 
where it functions as a constitutively active cation channel, which is highly permeable 
to Mg2+ and Ca2+ [66, 67, 69]. Subsequent studies demonstrated that at physiological 
membrane potentials (–80 - –40 mV), the channel is also able to conduct a wide range 
of physiological divalent cations, including Zn2+, Co2+, Mn2+ as well as nonphysiological 
cations such as Sr2+, Ba2+, Ni2+, and Cd2+ with the following permeability sequence of 
Zn2+ ≈ Ni2+ >> Ba2+ > Co2+ > Mg2+ ≥ Mn2+ ≥ Sr2+ ≥ Cd2+ ≥ Ca2+ [72]. However, in divalent 
cation-free intracellular solutions TRPM7 conducts monovalent cations quite well [66, 
67]. 
The biophysical characteristics of recombinant TRPM6 remain controversial. Two 
independent studies demonstrated that the human TRPM6 is not able to constitute 
functional homomeric channel complexes in the cell membrane when overexpressed in 
Xenopus oocytes and HEK 293 cells, but it needs TRPM7 to be co-targeted to the cell 
surface [77, 82]. In addition, heteromultimeric TRPM6/M7 channels seem to display 
different biophysical properties as compared to homomultimeric TRPM7 channel 
complexes [77, 79, 82, 91]. Oppositely, Voets et al. detected functional human TRPM6 
currents when the channel was heterologously expressed in HEK 293 cells [68] 
exhibiting high permeability to Zn2+, Mg2+, Ca2+, Ba2+, Mn2+, Sr2+, Cd2+ and Ni2+ [68, 82]. 
Recently, it was reported that the recombinant human TRPM6 cDNA can be 
functionally expressed only if it is inserted into pCINeo-IRES-GFP vector but not in 
other expression constructs [92].  
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1.2.1.4. Regulation of TRPM6 and TRPM7 channels 
TRPM6 and TRPM7 channels are regulated by several mechanisms. It is commonly 
accepted that one of the most important negative regulatory factors is intracellular 
content of free Mg2+ [67-69], ranging in most mammalian cells between 0.5 and 1 mM 
[93, 94]. IC50 values of 720 and 569 µM free Mg
2+ for recombinant [95] and native [92] 
TRPM7 channels, respectively, have been determined. Kozak and Cahalan [96] 
revealed that internal Mg2+ is not exclusive in its ability to inhibit TRPM7 currents, as 
Ba2+, Sr2+, Zn2+ and Mn2+ could also elicit inhibitory effect on TRPM7 currents. 
Experiments with recombinant human TRPM6 produced conflicting results regarding 
the sensitivity to intracellular Mg2+. One study concluded that human TRPM6 is 
suppressed by internal Mg2+ with IC50 values of 510 µM [68]. In other second study, 
human TRPM6 was found to be inhibited by very low Mg2+ levels with an IC50 of 29 µM 
[92]. 
Another physiologically relevant regulatory factor of the channel activity is intracellular 
free Mg·ATP (estimated in 3-7 mM in mammalian cells [93, 94]). Mg·ATP elicited its 
inhibitory effect on TRPM7 with an IC50 of 2 mM when internal Mg
2+ was buffered to 
physiological levels (~800 µM) [67, 95]. Because of the high sensitivity of TRPM7 to 
Mg2+ and Mg·ATP, TRPM7 currents are often named as Mg2+-inhibited cation (MIC) 
currents [97, 98] or magnesium nucleotide-regulated metal ion (MagNum) currents [67, 
99]. Mg·ATP could suppress human TRPM6 currents with IC50 of 1.3 mM in one study 
[100], but it was unable to inhibit human TRPM6 in other study [92]. Hence, regulatory 
properties of TRPM6 await further clarifications. 
Low external pH (~4.0) significantly enlarges TRPM6 and TRPM7 inward currents, by 
increasing the monovalent cation permeability of the channel, i.e., by removing the 
divalent cation block of the channel pore by divalent currents [101, 102]. On the other 
hand, TRPM7/MIC currents can be activated by elevated internal pH (~9.0) [103]. The 
physiological relevance of these regulatory mechanisms remains unknown. 
TRPM6 and TRPM7 are positively regulated by phosphatidylinositol 4,5-bisphosphate 
(PIP2) [73, 74]. It was shown that G protein–coupled receptors-mediated activation of 
phospholipase C (PLC) lead to PIP2 hydrolysis, with consequent inactivation of TRPM6 
and TRPM7, suggesting that both channels require PIP2 for its function [73, 74]. 
Recently, it has been reported that TRPM7 can function as a channel in intracellular 
membrane compartments [104]. Thus, the majority of TRPM7 was found to be 
localized in intracellular vesicles, referred to as M7Vs, containing high levels of 
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glutathione [104]. M7Vs are distinct from other organelles or vesicles as endosomes or 
lysosomes [104]. These vesicles are capable to accumulate Zn2+ when its cytosolic 
levels are elevated [104]. Reactive oxygen species (ROS) were able to trigger the 
release of Zn2+ from M7Vs into the cytosol via TRPM7 channel [104]. In addition, 
reduced levels of glutathione prevented TRPM7-dependent cytosolic Zn2+ raises [104]. 
The authors concluded that intracellular TRPM7 senses oxidative stress to release Zn2+ 
from M7Vs [104]. 
The role of the kinase domain in the regulation of the channel activity is not well 
understood. A currently prevailing view is that TRPM7 kinase is not necessary for 
channel activity [86]. However, some groups suggested that the TRPM7 kinase domain 
moderately regulates TRPM7 channel sensitivity to intracellular Mg2+ and Mg·ATP [69, 
95]. It has been shown that the function of TRPM7 kinase domain can be separated 
from the channel mojety. Thus, it was found that the caspase-dependent cleavage of 
TRPM7 resulted in a release of the kinase domain into the cytosol [105]. The cleaved 
channel unit was found to be crucial for the potentiation of Fas-induced apoptosis by 
TRPM7 in T cells [105]. The released kinase domain was able to translocate to the 
nucleus, where it can phosphorylate specific histones, resulting in epigenetic chromatin 
modification [106]. 
In contrast to the TRPM7 α-kinase domain, little is known about a role of the TRPM6 
kinase. One work suggested that the TRPM6 kinase is involved in an inhibitory action 
of ATP on the TRPM6 channel [100]. Similar to TRPM7, the C-terminal kinase domain 
of TRPM6 was recently found to be cleaved from the channel domain [107]. The 
cleaved TRPM6 kinase was able to translocate to the nucleus and interact with 
arginine methyltransferase 5 (PRMT5) molecular complex [107]. This interaction 
permitted TRPM6 kinase domain to phosphorylate serine and threonine residues of 
histones near arginines methylated by PRMT5 [107]. Histone phosphorylation by 
TRPM6 kinase domain resulted in decreased methylation of the arginine residues and 
large-scale alterations in gene expression profiles [107].  
 
1.2.1.5. Modulation of TRPM6 and TRPM7 by small organic drug-like ligands 
Several small organic compounds enable to inhibit or activate TRPM6 and TRPM7 
currents. 2-Aminoethyl diphenylborinate (2-APB) elicits an inhibitory effect on 
endogenous [108] and recombinant TRPM7 channels [91]. Surprisingly, TRPM6 
currents could be enhanced by 2-APB [91, 92]. 
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Waixenicin A, a compound extracted from the soft coral Sarcothelia edmondsoni [109], 
was found as a potent inhibitor of TRPM7, which blocked the channel irreversibly in a 
Mg2+-dependent manner. Thus, in the presence of physiologically relevant 700 µM 
cytosolic Mg2+, the IC50 was 16 nM. However, removing of Mg
2+ resulted in IC50 of 7 µM 
[109]. Importantly, waixenicin A does not affect TRPM6 [109]. 
Our laboratory identified a set of other potent TRPM7 inhibitors [110]. Among them, 
NS8593 was studied in details. NS8593 has an IC50 of 1.6 µM under free Mg
2+ internal 
conditions [110]. Similarly to waixenicin A, NS8593 acts on TRPM7 in a Mg2+-
dependent manner. The inhibitory effect of NS8593 on TRPM7 was fully reversible 
[110]. 
More recently, our laboratory identified a subset of TRPM7 activators, like naltriben 
[111] and mibefradil [112]. Naltriben activated TRPM7 currents without prior depletion 
of intracellular Mg2+ and exhibited an half-maximal effective concentration (EC50) of 20 
µM [111]. The effect of naltriben was fully reversible and interfered with the inhibitory 
action of NS8593 [111]. Mibefradil activated TRPM7 currents with an EC50 of 53 µM 
[112]. In contrast to naltriben, mibefradil stimulated TRPM7 currents only at 
physiological internal Mg2+ levels, and its activating effect was abolished by high 
intracellular Mg2+ concentrations [112]. 
 
1.2.1.6. The suggested physiological functions of TRPM7 
It has been demonstrated that chicken DT40 B lymphocytes with a targeted deletion of 
the Trpm7 gene developed Mg2+ deficiency and consequently growth arrest [67, 69]. 
The proliferation defect of these mutant cells were rescued by increasing Mg2+ (but not 
Ca2+, Zn2+ or Mn2+) in the culture medium [69]. Since the TRPM7 channel pore is 
permeable to Mg2+ ions, these observations led to the concept that the TRPM7 channel 
regulates cellular Mg2+ homeostasis in DT40 cells [69, 113, 114]. Endogenous TRPM7-
like currents have been observed in all cell types examined so far [110], indicating that 
TRPM7 plays a similar role in all vertebrate cells. In addition, several studies have 
suggested a plethora of other (patho)physiological processes regulated by the TRPM7 
channel, including cell motility [88, 115, 116], cell cycle [67, 69, 109, 114], 
mechanosensitivity [116-118], exocytosis [119], anoxic neuronal death [120], 
hypertension [121], neurodegenerative disorders [122, 123], cardiac fibrosis [124], and 
cancer [108, 125-127]. 
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A global disruption of TRPM7 in mice leads to early embryonic lethality prior day 7.5 of 
embryogenesis (e7.5) for unknown reasons [128]. The epiblast-specific inactivation of 
TRPM7 fails to produce viable KO mice, indicating that TRPM7 is required for 
embryonic development [128]. Furthermore, tissue- and organ-specific inactivation of 
Trpm7 in mouse embryos affected the normal development and function of internal 
organs, highlighting an essential role of TRPM7 in organogenesis [128, 129]. Thus, 
conditional inactivation of TRPM7 in the T-cell lineage disrupts thymopoiesis, without 
altering Mg2+ homeostasis [128]. Moreover, it has been shown that TRPM7 is 
indispensable for proper kidney development [129]. The role of TRPM7 has been also 
shown in cardiogenesis using mutant mice with specific ablation of Trpm7 in the 
embryonic heart [130, 131]. Early loss of cardiac TRPM7 causes heart failure and 
death, suggesting that TRPM7 is indispensable for myocardial morphogenesis [130]. In 
addition, TRPM7 has been shown to be essential for maintaining cardiac automaticity 
in adult mice [131]. 
It has been shown that mice with a complete deletion of the TRPM7 kinase domain die 
at e7.5 for unknown reasons [113]. Heterozygous mice lacking TRPM7 kinase domain 
exhibited an altered Mg2+ homeostasis, since they have lower Mg2+ concentrations in 
urine, plasma and bones [113]. In contrast, TRPM7 kinase-dead mutant mice 
containing a substitution of a key lysine involved in Mg·ATP binding had a normal 
development and unchanged serum Mg2+ levels [132]. In addition, TRPM7 kinase-dead 
mice were found to be more resistant to dietary Mg2+ deprivation [133]. Using the same 
mouse line with inactivation in the TRPM7 kinase domain, Zierler et al. showed that this 
domain is involved in mast cell degranulation and release of histamine [134]. Finally, it 
has been recently demonstrated that TRPM7 kinase plays a role in hypertension [135]. 
 
1.2.1.7. Physiological implications of the TRPM6 channel 
In 2002, two groups independently identified a loss-of-function mutation in the human 
TRPM6 gene leading to an autosomal recessive hypomagnesemia with secondary 
hypocalcemia (HSH) [70, 71]. This disorder, characterized by very low Mg2+ and Ca2+ 
serum levels, manifests shortly after birth with neurologic symptoms, including muscle 
spasms and seizures [70, 71]. Untreated, HSH may be fatal or may result in 
neurological damage; however, all the symptoms can be relieved by oral Mg2+ 
supplementation [70, 71]. The pathophysiological mechanisms of HSH are not well 
understood. For example, it remains unclear whether the disease is mainly caused by a 
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defect in the intestinal Mg2+ absorption or due to an abnormal renal loss of Mg2+ [70, 
71]. A considerable number of HSH mutations in the TRPM6 gene introduces stop and 
frame-shift mutations and affects exon splicing, causing a complete lack of protein 
production [70, 71, 77, 79, 136-141]. In addition, several point mutations in TRPM6 
have been identified [78]. Mutations characterized by our group are depicted on Fig. 
1.3B. One mutation, TRPM6S141L, is located in the N-terminal of the channel, implying a 
fundamental role of this domain for the channel activity [77]. Interestingly, the 
TRPM6S141L mutant fails to associate with TRPM7 [77]. P1017R, another missense 
mutation, is located in the TRPM6 putative pore-forming region [79]. TRPM6P1017R 
showed a dominant negative effect when it was co-expressed with TRPM7 [79]. 
Until now, only two groups studied mice strains lacking TRPM6. Walder et al. [142] 
revealed that Trpm6-/- mice almost never survived to weaning. Most mutant individuals 
died prior e12.5 [142]. The few survived mice beyond this stage showed massive 
neural tube defects (NTD) [142]. Feeding parents high Mg2+ diet did not improve the 
embryonic survival of the mutants [142]. Hence, the authors suggested that TRPM6 
plays a critical role in embryonic development and in neural tube closure. However, the 
specific molecular mechanisms underlying NTD in Trpm6 deficient mice are still 
unclear [142]. Employing another Trpm6 deficient mutant line (Trpm6βgeo), 
Woudenberg-Vrenken et al. [143] confirmed that homozygous null TRPM6 mutation 
leads to the embryonic death. However, mice heterozygous for Trpm6 deletion are 
viable and develop a mild hypomagnesemia [143]. A Mg2+-enriched diet neither 
rescued the embryos nor improved hypomagnesemia induced by Trpm6βgeo [143]. 
Thus, the targeted deletion of the mouse Trpm6 gene caused an unexpected 
phenotype in mice which differs from symptoms observed in HSH patients. 
Very recently, our group has confirmed that mice lacking Trpm6 (Trpm6βgeo/βgeo mice) 
are not viable [144]. KO embryos died at a mid-gestational stage (e12.5) exhibiting a 
smaller size compared to Trpm6+/+ embryos and NTD [144] (Fig. 1.4). Furthermore, the 
KO embryos were Mg2+ deficient [144]. Since diverse mouse lines develop NTD due to 
mutations in genes, which are active in the in the neural tube epithelium [145], e8.5 
embryos were examined for TRPM6 expression using in situ hybridization (ISH). 
Surprisingly, Trpm6 was not detectable in embryos, but specifically expressed in the 
yolk sac and placental labyrinth [144] (a more detailed expression of Trpm6 in the 
placenta is explained in section 1.3.2). 
Consequently, a conditional Trpm6 mutation was used for a specific inactivation of 
Trpm6 allele in the epiblast cells of the early embryo, but not in extraembryonic tissues 
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[144]. This approach produced vital offspring deficient in TRPM6, supporting an idea 
that TRPM6 activity in extraembryonic cells is required for prenatal development of 
mice. In follow-up experiments, it was found that adult TRPM6 deficient mice 
developed a severe organismal Mg2+ deficiency, shorter lifespan compared to WT mice 
and an accelerated aging-like phenotype [144]. All these phenotypes were fully 
reversed by dietary Mg2+ supplementation of mice [144]. Taken together, experiments 
with gene-modified mice have established a critical role of TRPM6 in systemic 
homeostasis of prenatal and adult mice. 
 
 
 
 
 
 
Figure 1.4. Comparison between Trpm6
+/+
 and Trpm6
βgeo/βgeo
 embryos. (A) At e9.5, the 
mutant embryo is smaller in size, not turned (S-shaped) and growth retarded compared with the 
control. The arrow shows the open neural tube of the mutant embryo. (B) At e10.5, the mutant 
embryo exhibits NTD. The unclosed neural tube in the head region is shown by an arrow. 
Figure modified from [144]. 
 
1.3. Mg2+ homeostasis 
Magnesium is the second most abundant intracellular cation playing a key role in the 
regulation of many cellular processes [93]. This essential element is a cofactor in over 
300 enzymatic reactions. Mg2+ controls the activity of enzymes by (i) binding to the 
active site of the enzyme, (ii) interaction with substrates such as ATP, (iii) causing a 
conformational changes of the enzyme leading to modulation of the catalytic reaction, 
or (iv) promoting the assembly of multi-enzyme complexes [93, 146, 147]. Mg2+ is also 
an essential structural factor of many proteins, nucleic acids, and a regulatory ligand of 
membrane transporter and channels [94, 147, 148]. Furthermore, Mg2+ is involved in 
many other vital processes such as nucleic acid and protein synthesis, cellular energy 
metabolism, mitochondrial and cytoskeletal integrity [94, 147]. Finally, Mg2+ operates as 
a Ca2+ channel antagonist; it alters processes regulated by intracellular Ca2+ and, thus, 
is critical for normal neurological and muscular functions [146, 147]. 
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The total cellular Mg2+ concentration ranges between 5 and 10 mM in the majority of 
mammalian cell types examined, and it can be up to 20 mM in some cells. Most ionized 
Mg2+ is bound to ATP and other nucleotides, sequestered in mitochondria, and endo-
(sarco)-plasmic reticulum [94, 149]. Accumulation of Mg2+ in these organelles is due to 
the ability of Mg2+ to bind to proteins, phospholipids, nucleic acids, nucleotides and 
chromatin [94, 149]. In the cytosol, Mg2+ forms complexes with adenosine 
trisphosphate (ATP) and other phosphometabolites [93, 94]. Free Mg2+ concentrations 
in the cytosol have been estimated to range between 0.5 and 1 mM (~10% of total 
cellular Mg2+) in the majority of cell types examined [93, 94]. 
 
1.3.1. Mg2+ channels and transporters 
The maintenance of the intracellular Mg2+ concentrations is regulated by a dynamic 
balance of Mg2+ uptake, intracellular Mg2+ storage, and Mg2+ efflux. Thus, similarly to 
other cations, Mg2+ is transported across the plasma membrane or the membrane of 
cellular organelles through channels (Mg2+ uptake into the cells) and exchanger 
mechanisms (Mg2+ extrusion from the cells) [94, 150]. Diverse channels transporting 
Mg2+ into the cell have been described in mammals. Some of these channels exhibit 
higher specificity for Mg2+, whereas other can conduct several other divalent cations. 
Mg2+ channels are located in the plasma membrane, in the mitochondrial membranes, 
ER or in Golgi [94, 150]. Known mammalian Mg2+ transporters are described below. 
Claudins. The first Mg2+ transporter found in mammals was paracellin-1 (PCLN-1) or 
claudin-16 [151]. This protein, encoded by Paracellin-1 (PCLN-1) gene, was identified 
in a genetic screening of patients affected by familial hypomagnesemia with 
hypercalciuria and nephrocalcinosis (FHHNC, OMIM 248250), a severe disorder 
characterized by fast and chronic renal failure due to massive renal Ca2+ and Mg2+ 
wasting [151]. PCLN-1 is a member of the claudin gene family, a group of tight junction 
proteins characterized by 4 TMs and cytoplasmic C- and N-termini [94]. Claudin-16 is a 
renal tight junction protein required for paracellular Mg2+ and Ca2+ fluxes across the 
nephron epithelial layers [151]. However, the mechanisms underlying these fluxes 
remain to be elucidated. A recent study has demonstrated that another claudin, 
claudin-19, is involved in the renal Mg2+ and Ca2+ reabsorption [152]. 
MagT1. MagT1, identified by Goytain and Quamme in human epithelial cells, was 
suggested as a Mg2+-selective plasma membrane transporter [153]. The murine 
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orthologue of MagT1 is expressed in many tissues, including the heart, kidney, liver 
and colon [153]. Transport of Mg2+ by MagT1 is likely voltage-dependent [153]. 
SLC41 proteins. The three members (A1, A2, and A3) of this gene family are remotely 
related to prokaryotic MgtE transporter [154]. The first member to be identified was 
SLC41A1 [155]. This protein is characterized by the presence of 10 TMs [155]. 
Functional expression of murine SLC41A1 in Xenopus laevis oocyte reveals that this 
transporter conducts Mg2+ but also Zn2+, Cu2+, Fe2+, Ba2+ and Co2+ [156]. SLC41A2 was 
identified in humans and mice and, similar to SLC41A1, is able to transport Mg2+ and 
other divalent cations [157, 158]. Recent work indicates that SLC41A3 plays a role in 
organismal Mg2+ homeostasis since its expression was specifically detected in DCT 
and intestine, and because SLC41A3 KO mice developed hypomagnesemia [159]. It 
has been demonstrated that SLC41A3 is present in the inner mitochondrial membrane 
and functions as a mitochondrial Mg2+/Na+ exchanger [160]. 
ACDP proteins. Wang et al. identified four different genes, ACDP1– 4, belonging to 
the human ACDP gene family [161]. ACDP proteins are conserved and also exist in 
prokaryotes [162]. They show a moderate sequence similarity to CorC transporter of 
Salmonella typhimurium involved in Mg2+ efflux [163]. Mammalian ACDP2 mediated the 
fluxes of Mg2+ and other divalent cations when heterologously expressed in Xenopus 
oocytes [164]. 
NIPA proteins. This family comprises four NIPA (NIPA 1-4) genes called after a non-
imprinted in Prader-Willi/Angelman syndrome, a genetic disorder characterized by 
complex symptoms [165, 166]. NIPA1 is expressed in many tissues, but is particularly 
abundant in the brain. NIPA1 functions as a Mg2+ transporter, but can conduct other 
divalent cations [167]. NIPA2 protein is a transporter that mediates selective Mg2+ flux. 
NIPA2 is widely expressed, but was found to be more abundant in the kidney [168]. 
Similarly to NIPA1, NIPA3 and NIPA4 mediate Mg2+ uptake [168]. 
MMgTs proteins. This gene family comprises two proteins named MMgT1 and MMgT2 
(Membrane Mg2+ Transporter 1 and 2) [169]. When exogenously expressed in Xenopus 
laevis oocytes, MMgT1 and MMgT2 transport Mg2+, but they can also conduct other 
divalent cations [169]. MMgT transcripts were detected many tissues. MMgT proteins 
are presumably located in the Golgi complex and post-Golgi vesicles [169]. 
Mrs2. The mitochondrial RNA splicing2 (Mrs2) protein is located in the inner 
mitochondrial membrane. Mrs2 was identified in a screening of genes involved in 
splicing of mitochondrial RNA in yeast [170, 171]. Structurally, human Mrs2 is distantly 
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related to bacterial CorA and yeast Alr genes, which are both located in the plasma 
membrane of prokaryotic cells [171, 172]. Heterologously expression of yeast Mrs2 
enhanced Mg2+ uptake, whereas the lack of this channel nearly abolished Mg2+ influx, 
implying that Mrs2 plays a crucial role in the regulation of mitochondrial Mg2+ balance 
[173]. 
 
1.3.2. Roles of TRPM6 and TRPM7 in organismal Mg2+ balance 
The healthy adult human body contains 22-26 g of Mg2+ [147]. Mg2+ is predominantly 
stored in bones (~85%) and skeletal muscle (~10%); less than 1% of body Mg2+ is 
present in the plasma [146, 147, 174]. 
Mg2+ homeostasis in humans is controlled by the intestinal Mg2+ absorption and renal 
Mg2+ excretion [147, 174, 175]. Mg2+ absorption occurs in the small and large intestine 
(colon) via two different mechanisms: an active transcellular and a passive paracellular 
transport pathway. At low intraluminal concentrations, Mg2+ is absorbed mainly via the 
transcellular pathway, which is driven by the active Mg2+ uptake in the apical cell 
surface of epithelial cells. The paracellular route becomes relevant when luminal Mg2+ 
concentration rises, and is underlined by passive Mg2+ transport via tight junctions 
formed by the epithelial cells [174-176]. The composition of the intestinal tight junctions 
involved in the Mg2+ transport is still controversial [176]. Mg2+ absorption in the small 
intestine is supposed to be mediated entirely by passive paracellular mechanism driven 
by electrochemical gradient. In the large intestine, Mg2+ is thought to be transported 
solely via the transcellular pathway [176] (Fig. 1.5). TRPM6 is highly expressed in 
epithelial cells of the colon [71, 144]. Recently, our group demonstrated that the Mg2+ 
uptake mediated by TRPM6 is principally important in the intestine since the gut-
specific ablation of TRPM6 in mice leads to hypomagnesemia, indicating that the WT 
kidney is not able to compensate the deletion of Trpm6 in the intestine [144]. 
In the kidney, approximately 80% of total serum Mg2+ is filtered in the glomeruli, with 
>95% being reabsorbed along the nephron back into the blood. Only 3–5% of the 
filtered Mg2+ is excreted with the urine at physiological conditions. Around 10–15% of 
filtered Mg2+ is re-absorbed in the proximal convoluted tubules, while 60–70% is 
passively re-absorbed in the thick ascending loop of Henle [147, 174-176]. This 
paracellular transport is mediated by claudin-16 and claudin-19 forming the epithelial 
tight junctions [152]. Only 5–10% of the filtered Mg2+ is reabsorbed via transcellular 
transport in the distal convoluted tubule (DCT). As there is no significant reabsorption 
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of Mg2+ in the distal tubule and collecting duct, DCT defines the final urinary Mg2+ 
excretion levels. TRPM6 is specifically expressed in DCT and thought to be 
responsible for a final regulation of urinary excretion of Mg2+ [147, 174-176] (Fig. 1.5). 
However, our experiments with mutant mice containing a specific inactivation of Trpm6 
in the kidney exhibited normal plasma Mg2+ levels [144]. This finding challenges the 
idea that TRPM6 plays an essential role in DCT segment of the kidney. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. A proposed model of transcellular Mg
2+
 transport in intestine, kidney and 
placenta mediated by TRPM6/M7 channel complexes. TRPM6 and TRPM7 channels 
transport Mg
2+
 via transcellular pathway. The paracellular Mg
2+
 transport occurring through the 
small spaces between the epithelial cells and the Na
+
-dependent Mg
2+
 extrusion are also 
represented. Figure modified from [177]. 
  
Placental Mg2+ supply for the embryo is poorly understood. The fully developed mouse 
placenta is organized into two main zones, called junctional and labyrinth zones [178] 
(Fig. 1.6A). The junctional zone contains mainly spongiotrophoblasts and glycogen-
containing cells releasing endocrine factors [178]. The labyrinth zone is involved in the 
materno-fetal transport of minerals (and likely Mg2+), nutrients and waste metabolites, 
and gas exchange. This zone consists of maternal blood spaces (sinusoids) and fetal 
capillaries organized in a labyrinth-like structure, separated by three layers of fetal 
trophoblasts. The first layer lining the maternal blood spaces is composed by large 
mononuclear trophoblasts followed by two layers of syncytiotrophoblasts forming 
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syncytiotrophoblasts layer I (SynT-I) and syncytiotrophoblasts layer II (SynT-II) [178, 
179]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. The structure of placenta in mouse and human. (A) The mouse placenta is 
organized in the junctional (formed by spongiotrophoblasts) and labyrinth zones. The labyrinth 
represents the maternal-fetal interface and contains three trophoblast layers, layer I 
(mononuclear trophoblasts), layers II (syncytiotrophoblasts layer I, SynT-I) and III 
(syncytiotrophoblasts layer II, SynT-II). (B) The human placenta comprises chorionic villi, 
trophoblast-derived structures (blue) and mesoderm-derived tissues (orange). Figure modified 
from [178].  
 
As mentioned in section 1.2.1.7, Trpm6 was found to be highly expressed in the 
endoderm layer of the yolk sac and in placental trophoblasts [144]. In particular, in the 
early phases of the morphogenesis of the labyrinth (e8.5), when SynT-I and SynT-II are 
still two distinguishable layers, Trpm6 expression was found in cells expressing SynA 
(marker of SynT-I cells), but not in cells positive for Gcm1 (marker of SynT-II cells) 
[144]. In the fully developed labyrinth (e14.5), Trpm6 was localized in the 
syncytiotrophoblasts as well [144]. It has been supposed that Mg2+ and other nutrients 
are exchanged via SynT-I/SynT-II layers via the transcellular pathway [144]. In 
addition, the endoderm cells of the yolk sac appear to play an essential role in Mg2+ 
transport of early embryo prior formation of the placental labyrinth [144]. Thus, 
experiments with gene-modified mice revealed that Trpm6 underlines Mg2+ transporters 
by the placental and yolk sac in mammals [144]. 
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Figure 1.7. ISH of fetal/placental samples. (A) ISH on serial paraffin sections derived from 
e8.5 Trpm6
+/+
 fetus. Specific antisense (left) and sense (right) DIG-labeled probes for Trpm6 
were used. The two boxes represent magnified regions of the chorion (CH) and yolk sac (YS), 
respectively, located in the middle. Trpm6 is detectable in the developing labyrinth (chorion) and 
in the endoderm layer of the yolk sac. NT = neural tube; GT = giant trophoblast. (B) ISH on 
serial paraffin sections derived from e8.5 Trpm6
+/+
 placenta employing DIG-labeled probes for 
Trpm6 (left), SynA (middle) and Gcm1 (right), respectively. Trpm6 is located in cells expressing 
SynA (the marker of SynT-I), but absent in cells positive for Gcm1 (the marker of SynT-II). (C) 
ISH on serial paraffin sections derived from e14.5 Trpm6
+/+
 placenta using antisense Trpm6 
probe. The box indicates positions of the magnified images. Trpm6 signal is limitied to the 
labyrinth (lab) and not detectable in the decidua (dec) and trophoblast giant cells (GT). Figure 
modified from [144]. 
 
Taken together, emerging evidence indicates TRPM6 is a master regulator of systemic 
Mg2+ balance during the prenatal development and in adult organism due to its activity 
primarily in the placental trophoblastic and intestinal epithelial cells. However, a specific 
cellular function of TRPM6 remains poorly understood and is discussed controversially 
in the scientific literature. 
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1.4. Aims of this work 
Emerging evidence indicates that TRPM6 and TRPM7 channels are critically involved 
in the regulation of Mg2+ homeostasis. However, the exact molecular functions of 
TRPM6 and TRPM7 remain incompletely understood. 
In the first part of this work, we aimed at elucidating the cellular role of TRPM7 using 
different cell lines deficient in TRPM7 protein. 
In the second part of this study, we were aimed to uncover the mechanisms underlying 
the TRPM6-dependent transport of Mg2+ in epithelial cells using trophoblast stem (TS) 
cells derived from TRPM6 deficient mice. 
The main findings with TS cells were further evaluated using recombinant TRPM6 
protein overexpressed in HEK 293 cells. Overall, our study revealed specific functional 
characteristics of TRPM6 and TRPM7, which appear to be central for the physiological 
role of these remarkable proteins. 
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2. Materials 
2.1. Chemicals, enzymes and commercial kits 
1,2-Bis(o-aminophenoxy)ethane-N,N,N′,N′-  Biotium, # 50001 
tetraacetic acid (BAPTA) 
10X PCR buffer for PCR with MgCl2   Sigma-Aldrich, # P2192 
2-Aminoethyl diphenylborinate (2-APB)  Sigma-Aldrich, # D9754 
2-Mercaptoethanol     Carl Roth, # 4227 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic Sigma-Aldrich, # H3375 
acid (HEPES) 
Adenosine 5′-triphosphate magnesium salt  Sigma-Aldrich, # A9187 
(Mg·ATP) 
Agarose      Carl Roth, # 3810 
Ammonium peroxydisulphate (APS)   Carl Roth, # 9592 
Bovine serum albumin (BSA)   Sigma-Aldrich, # A2153 
Bromophenol blue sodium salt   Carl Roth, # A512 
Calcium chloride dihydrate (CaCl2)   Carl Roth, # HN04 
Cesium hydroxide solution (CsOH)   Sigma-Aldrich, # 232068 
D-(+)-Glucose      Sigma-Aldrich, # G8270 
D-Mannitol      Sigma-Aldrich, # 63559 
dNTP mix (10 mM each)    Thermo Fisher Scientific, # R0192 
Ethylene glycol-bis(β-aminoethyl ether)-  Carl Roth, # 3054 
N,N,N',N'-tetraacetic acid (EGTA) 
Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich, # E6758 
Expand high fidelity     Roche, # 11732641001 
GeneJET gel extraction kit    Thermo Fisher Scientific, # K0691 
GenElute mammalian genomic DNA miniprep kit Sigma-Aldrich, # G1N350 
GenElute mammalian total RNA miniprep kit Sigma-Aldrich, # RTN70 
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GeneRuler 100 bp DNA ladder   Thermo Fisher Scientific, # SM0241 
Glycerol      Carl Roth, # 3783 
Glycine      Carl Roth, # 3908 
Hydrochloric acid 37%    Merck Millipore, # 100317 
Hydrogen peroxide solution    Sigma-Aldrich, # 16911 
L-Glutamic acid     Sigma-Aldrich, # G1251 
Luminol      Sigma-Aldrich, # 123072 
Magnesium chloride hexahydrate (MgCl2)  Carl Roth, # 2189 
Methanol      Carl Roth, # 4627 
Naltriben mesylate     Tocris, # 0892 
Neon transfection system 10 µl Kit   Thermo Fisher Scientific,  
# MPK1025 
N-Methyl-D-glucamine (NMDG)   Sigma-Aldrich, # M2004 
NS8593 hydrochloride    Tocris, # 4597 
p-Coumaric acid     Sigma-Aldrich, # C9008 
Phosphatase inhibitor cocktail (tubes A and B) Biotool, # B15001 
Pierce classic IP kit     Thermo Fisher Scientific, # 26146 
Poly-D-lysine hydrobromide    Sigma-Aldrich, # P7280 
Potassium chloride (KCl)    Carl Roth, # 6781 
Powdered milk     Carl Roth, # T145 
Protease inhibitor cocktail    Biotool, # B14001 
Protein quantification kit-rapid   Sigma-Aldrich, # 51254 
QuikChange site-directed mutagenesis kit  Agilent Technologies, # 200518 
REDTaq genomic DNA polymerase (1 U/µl) Sigma-Aldrich, # D0688 
RevertAid H minus first strand cDNA synthesis kit Thermo Fisher Scientific, # K1632 
Roti-GelStain      Carl Roth, # 3865 
Rotiphorese gel 30 (37,5:1)    Carl Roth, # 3029 
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SDS ultra pure     Carl Roth, # 2326 
SIGMAFAST protease inhibitor tablets  Sigma-Aldrich, # S8820 
Sodium chloride (NaCl)    Carl Roth, # 3957 
Sodium hydroxide (NaOH)    Carl Roth, # 6771 
Spectra multicolor broad range protein ladder Thermo Fisher Scientific, # 26634 
Spectra multicolor high range protein ladder Thermo Fisher Scientific, # 26625 
Tetramethylethylenediamine (TEMED)  Carl Roth, # 2367 
Tris(hydroxymethyl)-aminomethane (TRIS)  Carl Roth, # 4855 
TWEEN 20 (Polyethylene glycol sorbitan  Sigma-Aldrich, # P1379 
monolaurate) 
Zinc chloride (ZnCl2)     Carl Roth, # T887    
 
2.2. Cell culture media and supplements 
2-Mercaptoethanol for cell culture   Sigma-Aldrich, # M7522 
Dimethyl sulfoxide (DMSO)    Sigma-Aldrich, # D4540 
Dulbecco’s phosphate buffered saline (DPBS) Sigma-Aldrich, # D8537 
Eagle´s minimum essential medium (MEM)  Sigma-Aldrich, # M4655 
Fetal bovine serum (FBS)    Thermo Fisher Scientific, # 10270 
Fetal bovine serum, embryonic stem cell-qualified Thermo Fisher Scientific, # 16141 
Heparin sodium salt from porcine intestinal  Sigma-Aldrich, # H3149 
mucosa 
Hirudin      Providing by Attila Brown´s 
laboratory [180] 
Iscove's modified Dulbecco's medium (IMDM) Thermo Fisher Scientific,  
# 12440053 
Lipofectamine 2000 transfection reagent  Thermo Fisher Scientific, # 11668 
MEM non-essential amino acids solution (100X) Thermo Fisher Scientific, # 11140 
Penicillin-Streptomycin    Sigma-Aldrich, # P4333 
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Primary mouse embryo fibroblasts (PMEF)  Millipore, # PMEF-CF 
Recombinant human fibroblast growth factor-4 R&D Systems, # 235-F4 
(FGF-4) 
Recombinant human transforming growth factor R&D Systems, # 240-B 
beta 1 (TGF-β1) 
Recombinant human/mouse/rat activin A  R&D Systems, # 338-AC 
RPMI-1640 medium     Sigma-Aldrich, # R8758 
Sodium pyruvate solution    Sigma-Aldrich, # S8636 
Thrombopoietin (Thpo)    Providing by Attila Brown´s 
laboratory [180] 
Trypsin-EDTA solution    Sigma-Aldrich, # T3924 
  
2.3. Antibodies 
Table 2.1. Primary antibodies used in this study. 
Name Specificity Epitope sequence 
 
Supplier 
Anti-TRPM7 
[S74-25] 
Mouse monoclonal Ab 
against human and 
mouse TRPM7 
LKLPDLKRND YTPDKIIFPQ 
DESSDLNLQS GNSTKESEAT 
NSVRLML 
Abcam,                
# ab85016 
Anti-TRPM7 
[EPR4582] 
Rabbit monoclonal Ab 
against human and 
mouse TRPM7 
Not available 
Abcam,                
# ab109438 
Anti-TRPM6     
Ab 75 
Rabbit polyclonal Ab 
against mouse TRPM6 
CERDKNRSSLEDHTRL 
Eurogentec 
(custom made) 
Anti-TRPM6 
Guinea pig polyclonal 
Ab against mouse 
TRPM6 
GCERDKNRSSLERHTRL 
Abcam,                  
# ab47017 
Anti-(p)T1730 
TRPM6 
Rabbit polyclonal Ab 
against mouse 
(p)TRPM6 
RLSQ(p)TIPFTPIQC 
Eurogentec 
(custom made) 
Anti-β-Actin 
Peroxidase 
Mouse monoclonal Ab 
against β-actin 
DDDIAALVIDNGSGK 
Sigma-Aldrich,       
# A3854 
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Table 2.2. Secondary antibodies used in this study. 
Name Specificity Epitope sequence 
 
Supplier  
Anti-rabbit IgG 
HRP-linked 
(H+L chain) 
Goat Ab against rabbit Ig-G Not available 
Cell Signaling,     
# 7074 
Anti-guinea pig 
IgG HRP-linked 
(H+L chain) 
Rabbit Ab against guinea pig Ig-G Not available 
Acris,                   
# R1322HRP 
 
2.4. Oligonucleotides 
All oligonucleotides were produced in Metabion (Planegg-Martinsried) except for 
GAPDH primers, which were included in the RevertAid H Minus First Strand cDNA 
Synthesis Kit. 
 
Table 2.3. Oligonucleotides used in this study. 
Primer name Sequence (5’      3’) 
 
Amplicon 
(bp) 
 
Annealing 
temperature 
(°C) 
Trpm6
βgeo
-Fwd GCGTTGGCTACCCGTGAT 367 55 
Trpm6
βgeo
-Rev CTGATAAGGAAGGCTGCTCTAAG   
Trpm6
+
-Fwd ATGGAAAGTAAATGATGCGTGAA 464 52 
Trpm6
+
-Rev GGAAACTGACAGATGCCTTACTC   
Trpm7
Δ17
- Fwd TTATGGTTGCTGGGAATC 340 51 
Trpm7
Δ17
-Rev CACAATGACAATACTGAAAGAACT   
Trpm7
+
-Fwd GGATACATTCACTCAGCACTAACT 530 52 
Trpm7
+
-Rev CACTTATGAACTCAAAAACTGGA   
Trpm6RTa-Fwd GCTGCCAAATCTGCCACAAT 651 50 
Trpm6RTa-Rev TGCCCACAGTCCCATCATCACA   
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Table 2.3. Oligonucleotides used in this study (continued). 
Primer name Sequence (5’      3’) 
 
Amplicon 
(bp) 
 
Annealing 
temperature 
(°C) 
Trpm6RTb-Fwd CCAGCTCAAAAGACCCTCACAGATGC 586 56 
Trpm6RTb-Rev CACACCACATCTTTTCCGACCAG   
Trpm7RTa-Fwd TCCCCCAGAATTACGACAGAGACGAC 365 54 
Trpm7RTa-Rev CATTCACTATATCCAGCAGCACCCACAT   
Trpm7RTb-Fwd AGTAATTCAACCTGCCTCAA 287 50 
Trpm7RTb-Rev ATGGGTATCTCTTCTGTTATGTT   
hTrpm6RT-Fwd TGCCCTCCTGGTTCTTTTCTTACT 421 57 
hTrpm6RT-Rev TTTCTGATGTCACTCGGATTCGTT   
hTrpm7RT-Fwd GGAGTCCGCCCCGTGAGG 802 63 
hTrpm7RT-Rev TGACTTCCGCCCCATACTTTCCAACAG   
GAPDH-Fwd CAAGGTCATCCATGACAACTTTG 496 58 
GAPDH-Rev GTCCACCACCCTGTTGCTGTAG   
 
2.5. cDNA expression constructs 
Table 2.4. cDNA expression constructs used in the present study. 
Plasmid name Vector backbone Protein expressed Reference 
mTRPM6 pIRES WT mouse TRPM6 protein [181] 
mTRPM6 pcDNA3.1 TOPO-TA WT mouse TRPM6 protein [181] 
mTRPM6
K1810R
 pIRES 
‘Kinase-dead’ variant of mouse 
TRPM6 
[181] 
mTRPM6
T1730A
 pIRES 
‘Kinase-dead’ variant of mouse 
TRPM6 
[181] 
mTRPM7 pIRES WT mouse TRPM7 protein [110] 
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2.6. Buffers and standard solutions 
 
Tris-acetate-EDTA (TAE): 40 mM Tris, 1 mM EDTA, 20 mM acetic acid 
 
 
Solutions used for Western blot analysis:  
 
Loading buffer (2X Laemmli buffer): 250 mM TrisHCl pH 6.8, 40% Glycerin, 8% 
SDS, 0.04% Bromophenol blue, 1% β-mercaptoethanol 
 
Running gel: 6% acrylamide/bisacrylamide, 375 mM TrisHCl pH 8.8, 0.1% SDS, 0.1% 
APS, TEMED (1:1000) 
 
Stacking gel: 3% acrylamide/bisacrylamide, 125 mM TrisHCl pH 6.8, 0.1% SDS, 0.1% 
APS, TEMED (1:1000) 
 
Running buffer (Tris-Glycine-SDS (TGS)): 25 mM Tris, 190 mM glycine, 0,1% SDS 
 
Transfer buffer (Tris-Glycine-methanol (TGM)): 25 mM Tris, 190 mM glycine, 20% 
methanol 
 
Tris-buffered saline with Tween 20 (TBST): 20 mM Tris, 137 mM NaCl, 0,1% Tween 
20 
 
Blocking solution: 5% non-fat milk in TBST 
 
Stripping solution: 60 mM TrisHCl pH 6.8, 2% SDS, 0.7% β-mercaptoethanol 
 
Enhanced chemiluminescence (ECL) solution: 
Solution 1: 100 mM TrisHCl pH 8.5, 2.5 mM luminol, 0.4 mM p-coumaric acid 
Solution 2: 100 mM TrisHCl pH 8.5, 0.06% H2O2 
(Solution 1 and 2 were mixed 1:1 and used immediately for WB imaging) 
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2.7. Consumables 
Biosphere filter tip 20 Sarstedt, # 70.1116.210 
Biosphere filter tip 100 Sarstedt, # 70.760.212 
Biosphere filter tip 1000 Sarstedt, # 70.762.211 
Borosilicate glass with firepolished ends Science Products, # GB150TF-8P 
with filament 
Center-well organ cell culture dish, 60mm BD, # 353037 
Corning Costar cell culture plates (12-well) Sigma-Aldrich, # CLS3513 
Filtropur S 0.2 Sarstedt, # 83.1826.001 
Filtropur S 0.45 Sarstedt, # 83.1826 
Glass coverslips ø 12 mm Carl Roth, # P231.1 
Holders for standard retransfer & handling pipettes BioMedical Instruments 
Injekt-F Solo syringe 2 ml B|Braun; # 4606027 V 
Injekt Solo syringe 20 ml B|Braun; # 4606205 V 
Micropipettes MicroFil 28 g, 97 mm WPI; # MF28G-5 
Micro tube 0.5 ml, PP Sarstedt, # 72.699 
Micro tube 1.5 ml, PP Sarstedt, # 72.690.001 
Multiply-Pro cup 0.2 ml, PP Sarstedt, # 72.737.002 
Multiply-µStrip Pro 8-strip (PCR reaction tubes) Sarstedt, # 72.991.002 
Nitrocellulose membrane Amersham Protran GE Healthcare Life Sciences,  
0.45 µM # 10600002  
Norm-Ject syringe 10 ml Henke Sass Wolf, # 4100.000V0 
Parafilm M Pechiney Plastic Packaging;  
 # PM992 
Pasteur pipettes Carl Roth, # 4522 
Pipette tip 20µl Sarstedt, # 70.1116 
Pipette tip 200µl Sarstedt, # 70.760.002 
Pipette tip 1000µl Sarstedt, # 70.762 
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SafeSeal micro tube 2 ml, PP Sarstedt, # 72.695.500 
Serological pipette 2 ml Sarstedt, # 86.1252.001 
Serological pipette 5 ml Sarstedt, # 86.1253.001 
Serological pipette 10 ml Sarstedt, # 86.1254.001 
Serological pipette 25 ml Sarstedt, # 86.1685.001 
Standard retransfer & handling pipettes BioMedical Instruments 
Sterican needles ø 0,40 x 20 mm, 27 G X ¾ B|Braun; # 4657705 
TC dish 100, standard Sarstedt, # 83.3902 
TC dish 35, standard Sarstedt, # 83.1800 
TC flask T25, standard, ventilation cap Sarstedt, # 83.3910.002 
TC flask T75, standard, ventilation cap Sarstedt, # 83.3911.002 
TC plate 6-Well, standard, F Sarstedt, # 83.3920 
Tube 15 ml, 120x17 mm, PP Sarstedt, # 62.554.502 
Tube 50 ml, 114x28 mm, PP Sarstedt, # 62.547.254 
 
2.8. Equipment 
Table 2.5. Equipment employed in the present study. 
Instrument Model Supplier 
Air pressure control  MPCU-3 Lorenz Meßgerätebau 
Cell culture hood HERAsafe Thermo Fisher Scientific 
Centrifuges Heraeus Labofuge 400 Thermo Fisher Scientific 
 Heraeus Pico 17 Thermo Fisher Scientific 
Counting chambers  Neubauer, 0640110 Marienfeld Superior 
Electroporator Neon Transfection System Thermo Fisher Scientific 
Gel imaging systems Chemi-Smart-5100 PeqLab 
 Infinity-3026WL/26MX PeqLab 
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Table 2.5. Equipment employed in the present study (continued). 
Instrument Model Supplier 
Horizontal gel electrophoresis Compact M Biometra 
Incubator with CO2 HERAcell 240 Thermo Fisher Scientific 
Microelectrode Puller DMZ-UNIVERSAL-PULLER Zeitz Instruments 
Micromanipulator ACCi UC Scientifica 
Microscopes Axiovert 40 CFL ZEISS 
 
Axio Vert.A1 equipped with 
Power supply 12V 100W and 
COLIBRI.2 Controller 
ZEISS 
 
SteREO Discovery.V8 
equipped with Cold Light 
Source KL 2500 LCD 
ZEISS 
Microwave Microwave & Grill Severin 
Osmometer 
VAPRO Vapor Pressure 
5600 Wescor Inc 
Patch Clamp Amplifier EPC 10 USB HEKA 
pH Meter Lab 850 Schott Instruments 
Pipettes 
P10, P20, P200, P1000, 
P100 PeqLAb 
Power supply PowerPac HC Bio-rad 
 EV231 PeqLab 
Precision balance 572 Kern 
 ALT 220-5DAM Kern 
Rotator LD79 Labinco 
Shaker Mini Rocker MR-1 PeqLab 
Spectrophotometer BioPhotometer plus Eppendorf 
Thermocycler TProfessional TRIO Analytik Jena 
Thermo shaker TS-100 PeqLab 
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Table 2.5. Equipment employed in the present study (continued). 
Instrument Model Supplier 
Vertical gel electrophoresis Mini-PROTEAN Tetra Cell Bio-rad 
Vortexer TOP-MIX 94500 Bioblock Scientific 
 
2.9. Software 
Table 2.6. Software used in this project. 
Software Version Supplier 
Chemi-Capt 5000 v15.02 Vilber 
FitMaster  v2x53 HEKA 
Igor Pro v.6.2.2.2 Wavemetrics 
Infinity-Capt v14.2 Vilber 
IrfanView v4.36 Irfan Skiljan 
PatchMaster  v2x69 HEKA 
WEBMAXC STANDARD 12/31/03 maxchelator.stanford.edu 
ZEN 2 Pro V2.0.0.0 ZEISS Microscopy 
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3. Methods 
3.1. Isolation and characterization of Trpm6 and Trpm7 
deficient trophoblast stem (TS) cells 
3.1.1. Mouse strains 
For this study, we employed two different mutant mouse lines. The first line with a null 
mutation in Trpm6 (129S5/SvEvBrd-C57BL/6) was obtained from the Texas Institute for 
Genomic Medicine as previously reported [143]. These Trpm6 deficient mice were 
generated by a ‘gene-trap’ approach using a targeting vector containing a βgeo 
reporter sequence (βgeo), designed to replace the exons 2 and 3 of Trpm6 (Fig. 3.1). 
The βgeo sequence contained a splice acceptor site sequence (SP), a bacterial β-
galactosidase marker sequence (LacZ), an internal ribosome entry site (IRES) and a 
neomycin resistance cassette (NeoR) (Fig. 3.1). In the mutant allele (Trpm6βgeo), the 
endogenous Trpm6 promoter drove the expression of an aberrant transcript encoding 
only exon 1 of Trpm6 spliced to LacZ sequence, instead of WT mRNA, resulting in a 
loss-of-function mutation of TRPM6. Trpm6βgeo mice were crossed with C57BL/6J mice 
for six generations. 
 
 
 
 
 
 
Figure 3.1. Targeting strategy used for the generation of Trpm6
βgeo
 allele. The mutant locus 
contains a βgeo cassette (βgeo) instead of the genomic sequence encompassing exons 2 and 3 
of Trpm6. Consequently, the Trpm6 promoter drives the expression of the mutant transcript 
encoding bacterial β-galactosidase (LacZ) and neomycin resistance protein (Neo). SP = splice 
acceptor site; IRES = internal ribosome entry site. 
 
The second mouse line with a conditional mutation in Trpm7 (Trpm7fl/fl mice, 
129S6/SvEvTac) was provided by David Clapham from Harvard Medical School, 
Boston, USA [128]. Trpm7fl/fl allele was produced using a targeting vector with two 
intronic LoxP sites flanking exon 17 of the Trpm7 gene (Trpm7fl allele) (Fig. 3.2A). We 
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crossed Trpm7fl/fl females and Sox2-Cre transgenic males (expressing a Cre 
recombinase controlled by Sox-2 promoter [182]) to induce a deletion of exon 17 
(Trpm7Δ17 allele) in early embryo (Fig. 3.2B). The generated Trpm7Δ17/+ line was 
maintained by intercross of Trpm7Δ17/+ parents. In line with the original work [128], 
Trpm7Δ17/Δ17 offspring was never obtained, suggesting that Trpm7Δ17 allele is a true null 
mutation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Generation of Trpm7
Δ17/+
 mice (A) A null mutation of Trpm7 (Δ17) was generated 
by a Sox2-Cre mediated deletion of the floxed exon 17. (B) Breeding strategy for the generation 
of Trpm7
Δ17/+
 mice. Trpm7
fl/fl
 females were crossed with Sox2-Cre males to obtain mice 
heterozigous for Trpm7
Δ17 
allele. 
 
3.1.2. Mouse genotyping 
The mice were genotyped using PCR analysis of DNA isolated from tail fragments. The 
extraction of DNA was performed using GenElute mammalian genomic DNA miniprep 
kit (Sigma-Aldrich) according to the manufacturer´s instructions. PCR reaction 
contained 0.5 µl extracted DNA, 0.2 mM each dNTPs (Thermo Fisher Scientific), 1X 
REDTaq PCR buffer with MgCl2 included (Sigma-Aldrich), 0.4 µM oligonucleotides 
mixture (Metabion), 1 U REDTaq DNA polymerase (Sigma-Aldrich) to reach a final 
volume of 25 µl as outlined in Table 3.1. 
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Table 3.1. Master mix for PCR reaction. 
Reagent Initial concentration Final concentration Volume (µl) 
DNA extract   0.5 
REDTaq Buffer 10X 1X 2.5 
dNTPs 10 mM (each) 0.2 mM 0.5 
 Forward Primer 100 µM 0.4 µM 0.1 
Reverse Primer 100 µM 0.4 µM 0.1 
REDTaq Genomic DNA 
Polymerase 
1 U/µl 1 U 1 
Water   20.3 
  Total 25 
 
Trpm6βgeo allele was assessed using the following oligonucleotides: Trpm6βgeo-Forward 
5’-GCG TTG GCT ACC CGT GAT-3’ and Trpm6βgeo-Reverse 5’-CTG ATA AGG AAG 
GCT GCT CTA AG-3’. 367 bp amplicon was produced with the following PCR settings: 
 
Hot start 95°C 5 min  
Denaturation 95°C 30 sec  
Annealing 65°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 60 sec  
Denaturation 95°C 30 sec  
Annealing 55°C 30 sec 35 cycles 
Elongation 72°C 60 sec  
Final elongation 72°C 5 min  
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Trpm6+ allele was analyzed using the following oligonucleotides: Trpm6+-Forward 5’-
ATG GAA AGT AAA TGA TGC GTG AA-3’ and Trpm6+-Reverse 5’-GGA AAC TGA 
CAG ATG CCT TAC TC-3’. 464 bp amplicon was produced as follows: 
 
Hot start 95°C 5 min  
Denaturation 95°C 30 sec  
Annealing 62°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 60 sec  
Denaturation 95°C 30 sec  
Annealing 52°C 30 sec 35 cycles 
Elongation 72°C 60 sec  
Final elongation 72°C 5 min  
 
The following primer pair were used to detect the Trpm7Δ17 allele: Trpm7Δ17-Forward 5’-
TTA TGG TTG CTG GGA ATC-3’ and Trpm7Δ17-Reverse 5’-CAC AAT GAC AAT ACT 
GAA AGA ACT-3’. The amplified PCR product was 340 bp. We used the following PCR 
conditions: 
 
Hot start 94°C 5 min  
Denaturation 94°C 30 sec  
Annealing 61°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 60 sec  
Denaturation 95°C 30 sec  
Annealing 51°C 30 sec 40 cycles 
Elongation 72°C 60 sec  
Final elongation 72°C 5 min  
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To assess of Trpm7+ allele, we used the following oligonucleotides: Trpm7+-Forward 5’-
GGA TAC ATT CAC TCA GCA CTA ACT-3’ and Trpm7+-Reverse 5’-CAC TTA TGA 
ACT CAA AAA CTG GA-3’. 530 bp amplicon was generated using the following 
program: 
 
Hot start 94°C 5 min  
Denaturation 94°C 30 sec  
Annealing 62°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 60 sec  
Denaturation 95°C 30 sec  
Annealing 52°C 30 sec 35 cycles 
Elongation 72°C 60 sec  
Final elongation 72°C 5 min  
 
PCR reactions were carried out with TProfessional TRIO thermocycler (Analytik Jena). 
PCR products were separated by electrophoresis using 1% agarose gel in 1X Tris-
acetate-EDTA (TAE) buffer and stained with Roti-GelStain (Carl Roth). Gels were 
imaged using Infinity-3026WL/26MX (PeqLab). 
 
3.1.3. Housing of mice 
Animals were housed in individually ventilated polycarbonate cages (IVC System, 
Tecniplast, Germany) in the animal facility of WSI, LMU Munich. Cages were changed 
weekly. Mice were kept under a 12:12h light-dark cycle with artificial lighting. 
Temperature and relative humidity were 22+/–1°C and 50+/–5%, respectively. 
Breeding mice had free access to multigrain chow ssniff M-Z (#V1125, ssniff 
Spezialdiäten GmbH) and drinking water (ad libitum). Litters were weaned at three 
weeks of age, genotyped and maintained as described above except that a 
‘maintenance’ chow ssniff R/M-H (#V1535, ssniff Spezialdiäten GmbH) was used.  
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3.1.4. Isolation of TS cells 
Trophoblast stem cells were isolated as described earlier [183] with minor modifications 
[184, 185]. To produce WT (control) and Trpm6 deficient TS cells, we used Trpm6βgeo/+ 
parents. 3.5 days post-coitum blastocysts were isolated from sacrificed pregnant mice. 
Individual blastocysts were cultured in 12-well plates (Sigma-Aldrich) containing 
8x104/well irradiated primary mouse embryonic fibroblasts (PMEFs) (Millipore) in RPMI-
1640 medium (Sigma-Aldrich), 20% fetal bovine serum (FBS) (ES type, Thermo Fisher 
Scientific), 1 mM sodium pyruvate (cell culture type, Sigma-Aldrich), 100 µM β-
mercaptoethanol (cell culture tested, Sigma-Aldrich), 50 U/ml penicillin and 50 µg/ml 
streptomycin (Sigma-Aldrich), 1 µg/ml heparin (cell culture type, Sigma-Aldrich), 25 
ng/ml human recombinant FGF4, 5 ng/ml human recombinant TGF-β1, 10 ng/ml 
human/mouse/rat recombinant Activin A (all growth factors from R&D Systems) and 
additional 10 mM MgCl2 (Carl Roth). The 12-well plates containing the blastocysts were 
incubated in a humidified cell culture incubator (HERAcell 240, Thermo Fisher 
Scientific) at 37°C and 5% CO2. During the following 3 days, the blastocysts were 
monitored for hatching from the zona pellucida and attachment to the MEFs. The 
attached blastocysts were disaggregated using 0.05% trypsin-EDTA (Sigma-Aldrich) 
and further cultured as described above. Tight epithelial-like TS colonies were 
appeared after 3-7 days. The obtained TS clones were propagated in MEF-free 
conditions, genotyped and further cultured without additional Mg2+ in the medium. 
Trpm7 gene deficient and the relative control TS cells were obtained from mice 
heterozigous for Trpm7Δ17/+ allele as described above and maintained using the culture 
medium supplemented with 10 mM MgCl2. 
 
3.1.5. Maintaining of TS cell lines 
TS cells were cultured in MEF-free conditions at 37°C, 5% CO2 in T25 flasks (Sarstedt) 
using the TS medium described above. Additional 10 mM MgCl2 were included only to 
the cell culture medium of Trpm7 gene deficient cells. The cells were passaged every 
3-4 days. The cell culture medium was aspirated, the cells were washed with 
Dulbecco’s phosphate-buffered saline (DPBS) (Sigma-Aldrich) and 0.05% trypsin-
EDTA was added, followed by 3 minutes incubation at 37°C. The trypsin reaction was 
terminated by adding the TS medium and the cells were gently disaggregated by 
pipetting. After centrifugation (1.200 g, 2 min, RT), the cell pellet was resuspended in 
fresh medium and transferred to a new flask. For long-term storage, aliquots of TS cells 
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were kept in liquid nitrogen. For cryopreservation, TS cells were trypsinated, pelleted 
and resuspended in TS medium containing 50% FBS, 30% TS medium and 20% 
DMSO (Sigma-Aldrich). TS cells were placed in Mr. Frosty freezing container (Thermo 
Fisher Scientific) and incubated at –80°C overnight. The next day, TS cells were 
passed to a tank with liquid nitrogen. 
To determine whether Trpm6 and Trpm7 deficient TS cells were able to proliferate in a 
regular medium without Mg2+ supplementation, TS cells were seeded in 6-well plates 
(1x105 cells/well) in a medium supplemented with 10 mM Mg2+ (day 0). After 24 h (day 
1), the cells were washed twice with PBS and a fresh culture medium with or without 
Mg2+ (10 mM) was added. Cell density was examined 24 (day 2), 48 (day 3) and 72 h 
(day 4) using a Neubauer chamber (Marienfeld Superior). To calculate growth rates, 
cell density at day 1 was considered as 100% (mean+/-SEM). The experiment was 
repeated 3 times. Two-tailed t-test was applied for comparison of growth rates of 
Trpm6 or Trpm7 deficient vs corresponding control cells. 
Genotype of TS clones were determined by PCR analysis of extracted genomic DNA, 
using the same reagents and conditions reported above for the mouse genotyping. 
TS cells were electroporated using Neon Transfection System (Invitrogen). 1x105 cell 
suspension containing 2 µg cDNA pcDNA-IRES-TRPM6 expression plasmid were 
electroporated with the following program: pulse voltage 1000 v, pulse width 30 ms and 
pulse number 2. The cells were examined 24 h after electroporation. 
 
3.2. Generation of TRPM7 deficient HAP1 cells 
Human near-haploid (HAP1) cells was derived from the male chronic myeloid leukemia 
(CML) cell line KBM-7 [186-189]. TRPM7 deficient (KO) HAP1 cells (clone 10940–04) 
were engineered from parental HAP1 cell line (clone C631) using CRISPR/Cas9 
system in Horizon Genomics (Vienna, Austria) [144]. 
HAP1 clones were cultured in Iscove’s modified Dulbecco’s medium (IMDM) (Thermo 
Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher 
Scientific) and 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich). The KO 
clone was cultured in the presence of additional 10 mM MgCl2 (Carl Roth). Cells were 
maintained in a humidified cell culture incubator (HERAcell 240, Thermo Fisher 
Scientific) at 37°C and 5% CO2. HAP1 cells were passaged twice a week in T75 flask 
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(Sarstedt). For electrophysiological experiments, the cells were passaged and seeded 
directly on glass coverslips (Carl Roth). 
To study whether TRPM7 deficient and control HAP1 cells were able to proliferate in a 
regular medium without Mg2+ supplementation, we performed experiments similarly to 
studies described for TS cells (see section 3.1.5). 
For the long-term storage in liquid nitrogen, the cells were pelleted by centrifugation 
and resuspended in IMDM medium with 20% FBS. Next, an equal amount of IMDM 
medium containing 20% FBS and 20% DMSO (Sigma-Aldrich) was added to the 
cellular suspension, placed in Mr. Frosty freezing container (Thermo Fisher Scientific) 
and incubated at –80 C overnight. The next day, cells were passed to a tank with liquid 
nitrogen. 
 
3.3. Assessment of primary mouse megakaryocytes 
The primary megakaryocytes (MKs) were isolated from the bone marrow of either 
Trpm7fl/fl mice or mice with a conditional megakaryocytes-specific Trpm7 mutation 
Trpm7fl/fl;Pf4cre mice) using a negative depletion strategy as described in [180]. 
Trpm7fl/fl;Pf4cre mice were generated by intercrossing Trpm7fl/fl mice (Fig. 3.2A) with 
mice carrying the Cre recombinase under a control of the platelet factor 4 (Pf4) 
promoter [190]. The obtained cells were cultured in MK-medium containing IMDM 
(Thermo Fisher Scientific), 10% FBS (Thermo Fisher Scientific), 1% non-essential 
amino acids (NEAA) (Thermo Fisher Scientific), 100 U/ml penicillin and 100 µg/ml 
streptomycin (Sigma-Aldrich), 0.5% thrombopoietin (Thpo) and 50 μg/ml recombinant 
hirudin (both reagents are provided by Dr. Attila Braun´s laboratory) at 37 °C and 5% 
CO2 for 3 days. 
MK fraction was enriched immediately prior patch-clamp experiments as follows. The 
cells were centrifuged (200 g, 5 min, RT) and resuspended in 1.5 ml MK medium. The 
bovine serum albumin (BSA) gradient was produced in a 15 ml tube with 1.5 ml volume 
using two buffers containing 1.5% and 3% BSA. MKs were placed on the top of BSA 
gradient, allowed to sediment during 30 min at RT. The obtained cell pellet was 
resuspended in 3 ml MK medium, centrifuged (200 g, 5 min, RT) and resuspended in 2 
ml MK medium. The cell suspension was transferred onto glass coverslips (Carl Roth) 
for patch-clamp experiments (see 3.8). 
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3.4. Culture and transient transfection of HEK 293 cells 
Human embryonic kidney (HEK) 293 cells were cultured in Eagle´s minimum essential 
medium (MEM) (Sigma Aldrich) supplemented with 10% FBS (Thermo Fisher 
Scientific) and 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich). Cells 
were maintained in a humidified cell culture incubator (HERAcell 240, Thermo Fisher 
Scientific) at 37°C and 5% CO2. For electrophysiological experiments, the cells were 
seeded in 6-well plates (Sarstedt) (~105 cells/well). The next day, the cells were 
transiently transfected with various cDNA plasmids (1 or 2 µg/well as indicated in the 
text) using Lipofectamine 2000 reagent (Thermo Fisher Scientific) according to the 
manufacturer´s instructions. We performed experiments 24h after transfection. 
 
3.5. Generation of mouse TRPM6 cDNA expression constructs 
cDNA encoding mouse TRPM6 (NCBI accession KX375810) was cloned in pIRES2-
EGFP (Clontech) expression vectors as reported before [181]. K1810R and T1730A 
point mutations in mouse TRPM6 were introduced by site-directed mutagenesis 
(QuikChange kit, Agilent Technologies) and confirmed by sequencing. The mouse 
TRPM7 expression constructs in pIRES2-EGFP vector was reported previously [191]. 
3D predictions of the TRPM6 kinase domain structure were generated as reported 
previously [79, 191] using MODELLER (modbase.compbio.ucsf.edu/modweb) and 
UCSF Chimera (www.cgl.ucsf.edu/chimera). 
 
3.6. Reverse transcriptase PCR (RT-PCR) analysis 
Total RNA was extracted from cell pellets using the GenElute mammalian total RNA 
miniprep kit (Sigma-Aldrich). RNA content was determined using a spectrophotometer 
(BioPhotometer plus, Eppendorf). RNA was converted into a complementary DNA 
(cDNA) by the RevertAid H Minus M-MuLV reverse transcriptase (Thermo Fisher 
Scientific). 1 µg total RNA were processed using 0.2 µg random hexamer primers mix, 
1 mM dNTPs mix, reaction buffer (containing 250 mM Tris-HCl pH 8.3, 250 mM KCl, 20 
mM MgCl2, 50 mM DTT), 20 U RiboLock RNase inhibitor and 200 U RevertAid H Minus 
M-MuLV reverse transcriptase as outlined in Table 3.2. The reverse-transcription 
reaction was performed for 5 min at 25°C, followed by 60 min incubation at 42°C and 
heat-terminated for 5 min at 72°C. 
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Table 3.2. Master mix for reverse-transcriptase reaction. 
Reagent Initial concentration Final concentration Volume (µl) 
Total RNA   1 µg 
Random Hexamer Primer 100 µM (0.2 µg/µL) 5 µM (0.2 µg) 1 
dNTPs Mix 10 mM 1 mM 2 
 Reaction Buffer 5X 1X 4 
RiboLock RNase Inhibitor 20 U/µl 20 U 1 
RevertAid H Minus M-MuLV 
Reverse Transcriptase 
200 U/µl 200 U 1 
Water   to 20 µl 
  Total 20 
 
3.6.1. RT-PCR analysis of Trpm6 deficient TS cells 
The obtained cDNA was used for PCR analysis using REDTaq DNA polymerase. To 
detect Trpm6 transcripts in Trpm6 deficient TS cells, we used two different primer 
pairs. Trpm6RTa-Forward 5’-GCT GCC AAA TCT GCC ACA AT-3’ and Trpm6RTa-
Reverse 5’-TGC CCA CAG TCC CAT CAT CAC A-3’ primers were used to generate 
651 bp amplicon: 
 
Hot start 94°C 5 min  
Denaturation 94°C 30 sec  
Annealing 60°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 60 sec  
Denaturation 94°C 30 sec  
Annealing 50°C 30 sec 30 cycles 
Elongation 72°C 60 sec  
Final elongation 72°C 5 min  
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The second PCR reaction (586 bp amplicon) was performed using Trpm6RTb-Forward 
5’-CCA GCT CAA AAG ACC CTC ACA GAT GC-3’ and Trpm6RTb-Reverse 5’-CAC 
ACC ACA TCT TTT CCG ACC AG-3’ primers with the following PCR settings: 
 
Hot start 94°C 5 min  
Denaturation 94°C 30 sec  
Annealing 66°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 60 sec  
Denaturation 94°C 30 sec  
Annealing 56°C 30 sec 35 cycles 
Elongation 72°C 60 sec  
Final elongation 72°C 5 min  
 
Expression of Trpm7 in TS cells was study using Trpm7RTa-Forward 5’-TCC CCC 
AGA ATT ACG ACA GAG ACG AC-3’ and Trpm7RTa-Reverse 5’- CAT TCA CTA TAT 
CCA GCA GCA CCC ACA T-3’ primers (365 bp amplicon) and the following PCR 
conditions:  
 
Hot start 94°C 3 min  
Denaturation 94°C 30 sec  
Annealing 54°C 30 sec 25 cycles 
Elongation 72°C 60 sec  
Final elongation 72°C 5 min  
 
3.6.2. RT-PCR analysis of Trpm7 deficient TS cells 
We employed Trpm7RTb-Forward 5’-AGT AAT TCA ACC TGC CTC AA-3’ and 
Trpm7RTb-Reverse 5’-ATG GGT ATC TCT TCT GTT ATG TT-3’ primers to detect 
Trpm7 transcripts (287 bp product) with the following conditions: 
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Hot start 94°C 5 min  
Denaturation 94°C 30 sec  
Annealing 60°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 60 sec  
Denaturation 94°C 30 sec  
Annealing 50°C 30 sec 35 cycles 
Elongation 72°C 60 sec  
Final elongation 72°C 5 min  
 
To study Trpm6 transcripts, we used primers (Trpm6RTb) described for Trpm6 
deficient TS cells (see 3.6.1). 
 
3.6.3. RT-PCR analysis of TRPM7 deficient HAP1 cells 
For the detection of TRPM6 and TRPM7 transcripts in HAP1 cells, we used another set 
of primers since these cells have a human origin. The primers hTrpm6RT-Forward 5’- 
TGC CCT CCT GGT TCT TTT CTT ACT-3’ and hTrpm6RT-Reverse 5’-TTT CTG ATG 
TCA CTC GGA TTC GTT-3’ were used to probe TRPM6 expression (421 bp) with the 
following conditions: 
 
Hot start 95°C 5 min  
Denaturation 95°C 30 sec  
Annealing 67°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 60 sec  
Denaturation 95°C 30 sec  
Annealing 57°C 30 sec 40 cycles 
Elongation 72°C 60 sec  
Final elongation 72°C 5 min  
 
Methods 
 
 
 
47 
 
The primers hTrpm7RT-Forward 5’-GGA GTC CGC CCC GTG AGG -3’ and 
hTrpm7RT-Reverse 5’-TGA CTT CCG CCC CAT ACT TTC CAA CAG-3’ were used to 
detect TRPM7 (802 bp) with the following conditions: 
 
Hot start 95°C 5 min  
Denaturation 95°C 30 sec  
Annealing 73°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 90 sec  
Denaturation 95°C 30 sec  
Annealing 63°C 30 sec 35 cycles 
Elongation 72°C 90 sec  
Final elongation 72°C 5 min  
 
Expression levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 
assessed using the primer pair GAPDH-Forward 5’-CAA GGT CAT CCA TGA CAA 
CTT TG-3’ and GAPDH-Reverse 5’-GTC CAC CAC CCT GTT GCT GTA G-3’ and the 
following conditions (496 bp amplicon): 
 
Hot start 94°C 5 min  
Denaturation 94°C 30 sec  
Annealing 68°C 30 sec 10 cycles (–1°C per cycle) 
Elongation 72°C 30 sec  
Denaturation 94°C 30 sec  
Annealing 58°C 30 sec 35 cycles 
Elongation 72°C 30 sec  
Final elongation 72°C 5 min  
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PCR reactions were carried out in TProfessional TRIO thermocycler (Analytik Jena). 
Amplified PCR products were stained with Roti-GelStain (Carl Roth) and visualised by 
electrophoresis using 1% agarose gel in 1X TAE buffer. The gels were examined using 
Infinity-3026WL/26MX gel imaging system (PeqLab). 
  
3.7. Western blot analysis 
3.7.1. Assessment of recombinant TRPM6 and TRPM7 proteins in HEK 293 
cells 
HEK 293 cells cultured in 6-well plates (~50% confluence) were transfected with WT or 
mutant variants of mouse TRPM6 cDNAs using Lipofectamine2000 reagent (see 3.4). 
24 h after transfection, the cells were lysed using 300 µl/well Pierce IP lysis buffer 
(Thermo Fisher Scientific) supplemented with 3 µl protease inhibitor cocktail (Biotool) 
and 6 µl phosphatase inhibitor cocktail solution (Biotool). After centrifugation (13.000 g, 
1 min, 4°C), the supernatant was collected in a fresh 1.5 ml tube. Next, the cell lysates 
were diluted 1:1 with 2X Laemmli buffer (supplemented with 1% β-mercaptoethanol) 
followed by heating at 70°C for 10 minutes, aliquoted (20 µl) and stored at –80 °C. 
20 µl of the cell lysates were subjected to a sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at +120 mV in Mini-PROTEAN Tetra Cell unit (Bio-rad). 
6% polyacrylamide gel (Rotiphorese gel 30, Carl Roth) was used. Separated proteins 
were transferred from the gel to a nitrocellulose membrane (GE Healthcare Life 
Sciences) using Mini-PROTEAN Tetra Cell transfer unit for ~12h at 150 mA. Next, the 
membrane was incubated in Tris-buffered saline (TBS)/0.1% Tween (TBST) 
supplemented with 5% non-fat dry milk (Carl Roth) for 1 hour at RT. The membranes 
were incubated for ~12h at 4°C with primary antibodies diluted in TBST and 5% BSA 
(Sigma-Aldrich). A guinea pig anti-TRPM6 polyclonal antibodies (Abcam, ab47017) 
were used to detect TRPM6 (1:4000 dilution), whereas a rabbit monoclonal anti-
TRPM7 [EPR4582] antibody (Abcam, ab109438) (1:2000) was used to detect TRPM7. 
To assesses autophosphorylation of TRPM6, 1 µg/ml anti-(p)T1730 mouse TRPM6 
polyclonal antibodies (Eurogentec) was used. Next, the membranes were washed (x3) 
with TBST and incubated for 1 hour at RT with corresponding horseradish peroxidase 
(HPR) labeled antibodies diluted 1:1000 in TBST and 5% BSA. The secondary 
antibodies were either goat anti-rabbit IgG (Cell Signaling, 7074) or rabbit anti-guinea 
pig IgG (Acris, R1322HRP). After washing with TBST (x3), the membranes were 
examined using an enhanced chemiluminescence (ECL) reagent and Chemi-Smart-
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5100 (PepLab). As a loading control, β-actin was detected in the same cell lysates 
using mouse anti-β-Actin-HPR (1:50000) (Sigma-Aldrich, A3854) as described above. 
 
3.7.2. Assessment of endogenous TRPM6 and TRPM7 in TS and HAP1 
cells 
To detect native TRPM6 and TRPM7 proteins, we performed immunoprecipitation (IP) 
of TRPM6 and TRPM7 followed by Western blot analysis. IP was conducted with 
Pierce Classic IP kit (Thermo Fisher Scientific) according to the manufacturer´s 
instructions. Briefly, TS or HAP1 cells grew at ~80% confluence in 100 mm dish. Cell 
lysates were obtained by treatment of the cells by ice-cold 800 µl lysis buffer provided 
by the kit supplemented with 1.5 mg/ml SIGMAFAST Protease Inhibitor mix (Sigma-
Aldrich). The cell lysates were assessed for protein contents (Protein Quantification Kit-
Rapid, Sigma-Aldrich) and their volumes were adjusted to obtain an equal 
concentration of total proteins in control vs KO samples. Next, 500 µl of the cell lysates 
were incubated with 10 µg of either anti-TRPM6 or anti-TRPM7 antibodies for 1 h at 
4°C using a rotation setup (Labinco). The rabbit anti-TRPM6 Ab 75 polyclonal 
antibodies (Eurogentec) were used for TRPM6 IP, whereas the mouse anti-TRPM7 
[S74-25] monoclonal antibody (Abcam, ab85016) was employed for TRPM7 IP. Next, 
20 µl suspension of A/G proteins immobilized on agarose beads were added to the cell 
lysates and the tubes were incubated for ~12 h at 4°C at the rotation. The beads were 
precipitated by centrifugation (1.000 g, 1 min) and washed 3x with 200 µl of the 
lysis/wash buffer. Finally, 50 µl 2X Laemmli buffer containing 1% β-mercaptoethanol 
was added to the individual IP samples and immune complexes were dissociated by 
incubation of the beads at 70°C for 10 minutes. Lastly, the obtained IP samples were 
loaded to 6% SDS-PAGE and Western blot analysis was performed as described 
above. 
 
3.8. Patch-clamp assessment of TRPM6 and TRPM7 currents  
~1 h before performing electrophysiological experiments, the cells were dissociated by 
trypsin and placed on 12 mm glass coverslips (Carl Roth) covered with poly-D-lysine 
(0.1 mg/ml) (Sigma-Aldrich). The cells were allowed to adhere by incubating for ~1 h in 
a humidified cell culture incubator (HERAcell 240, Thermo Fisher Scientific) at 37°C 
and 5% CO2 in the corresponding cell culture medium. Next, the culture medium was 
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replaced by different physiological saline (see 3.8.1 and 3.8.2) and the cells were 
studied at RT (22-25°C) during 1 h. 
We used a tight-seal whole-cell configuration. Currents were recorded using an EPC10 
patch-clamp amplifier (HEKA) controlled by PatchMaster software (v2x69, HEKA). Data 
were analysed using FitMaster (v2x53, HEKA) and Igor Pro (v.6.2.2.2, Wavemetrics) 
software. Patch pipettes were made of borosilicate glass with fire-polished ends with 
filament (Science Products) and had resistances between 2.6 to 3.4 MΩ after filling 
with the Cs-glutamate based standard internal solution. All voltages were corrected for 
a liquid junction potential of +10 mV between external and internal solutions when 
internal solutions contained glutamate. Currents were elicited by 50 ms ramps from      
–100 to +100 mV (0.5 Hz) with 0 mV holding potential. Inward and outward current 
amplitudes were acquired at –80 mV and +80 mV, normalized to the cell size (pA/pF) 
and plotted versus time. Capacitive currents and series resistance (Rs) were 
determined and corrected before each ramp using the automatic capacitance 
compensation of the software. Series resistance compensation of 80% was used to 
reduce voltage errors in all experiments. 
To determine IC50 values, data were fitted with the Hill equation: 
 E(c) = Emax x (c
h/(IC50
h + ch)) 
with E being the effect/current at a given concentration c of activator/inhibitor, Emax the 
maximally achievable effect, IC50 the half-maximal concentration and h the Hill factor.  
 
3.8.1. Examination of the endogenous TRPM7-like currents in TS, HAP1 
and MK cells 
As described above (3.8), the cells were grown on glass coverslips. The coverslips 
were transferred to 35 mm cell culture dishes containing a standard external solution 
comprising (mM): 140 NaCl, 3 CaCl2, 2.8 KCl, 10 HEPES-NaOH and 11 glucose 
(Sigma-Aldrich or Carl Roth as outlined in section 2.1). For some experiments 
(indicated in the text), an external solution contained 1 mM CaCl2 and 2 mM MgCl2 
instead of 3 mM CaCl2. The divalent cation-free (DVF) extracellular solution contained 
(in mM): 140 NaCl, 2.8 KCl, 5 Na-EDTA, 10 HEPES-NaOH and 11 glucose. Unless 
stated otherwise, the divalent cation-free intracellular solution contained (in mM): 120 
Cs-glutamate, 8 NaCl, 5 Cs-EDTA, 10 Cs-EGTA and 10 HEPES-CsOH (Carl Roth and 
Sigma-Aldrich, as outlined in 2.1). 
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To obtain Mg2+ concentration-response datasets, the intracellular pipette solution 
comprised (in mM): 120 Cs-glutamate, 8 NaCl, 10 Cs-BAPTA (Biotium), 10 HEPES-
CsOH and different amount of MgCl2 and Cs-EDTA as outlined in Table 3.3. To access 
the Mg·ATP concentration-response, the intracellular solution contained (in mM): 120 
or 140 Cs-glutamate, 8 NaCl, 2.7 Cs-EDTA, 10 HEPES-CsOH, and different amount of 
Mg·ATP (Sigma-Aldrich) and MgCl2 as indicated in Table 3.4. Concentrations of either 
free Mg2+ or Mg ATP were calculated by WebMaxC (maxchelator.stanford.edu) using 
the following settings: 25 °C, pH 7.2 and 0.16 empirical ionic equivalents. All the 
solutions were adjusted to pH 7.2 with Lab 820 pH-meter (Schott Instruments) using 
either CsOH (for internal solutions) or NaOH (for external solutions). Osmolarity of the 
internal solutions was adjusted to 285-295 mOsm using Vapro®Vapor Pressure 
Osmometer model 5600 (Wescor Inc.). 
 
Table 3.3. Internal solution used for examining of Mg
2+
 concentration-response of native 
currents in TS cells. 
free [Mg
2+
]i 
(µM) 
Cs-glutamate 
(mM) 
NaCl 
(mM) 
Cs-HEPES 
(mM) 
Cs-BAPTA 
(mM) 
Cs-EDTA 
(mM) 
MgCl2 
(mM) 
0 120 8 10 10 5 0 
0 120 8 10 10 0 0 
30 120 8 10 10 0.1 0.13 
88 120 8 10 10 0.1 0.21 
233 120 8 10 10 0 0.3 
390 120 8 10 10 0 0.5 
782 120 8 10 10 0 1 
1176 120 8 10 10 0 1.5 
2370 120 8 10 10 0 3 
4799 120 8 10 10 0 6 
 
 
 
 
Methods 
 
 
 
52 
 
Table 3.4. Internal solution used to determine Mg·ATP concentration-response of endogenous 
currents in TS cells. 
[Mg·ATP]i 
(mM) 
free [Mg
2+
]i 
(µM) 
Cs-
glutamate 
(mM) 
NaCl 
(mM) 
Cs-
HEPES 
(mM) 
Cs-
EDTA 
(mM) 
Mg·ATP 
(mM) 
MgCl2 
(mM) 
0.25 250 140 8 10 2.7 0.36 2.81 
0.5 250 140 8 10 2.7 0.8 2.68 
1 250 140 8 10 2.7 1.44 2.5 
1.5 250 140 8 10 2.7 2.2 2.27 
2 250 140 8 10 2.7 2.9 2.07 
2.75 250 140 8 10 2.7 3.9 1.77 
3.5 250 140 8 10 2.7 5 1.45 
5 250 120 8 10 2.7 7.1 0.83 
6 250 120 8 10 2.7 8.5 0.42 
7 250 120 8 10 2.7 10 0 
8 260 120 8 10 2.7 11 0 
 
3.8.2. Patch-clamp experiments with recombinant TRPM6 and TRPM7 
The transfected HEK 293 cells were seeded on the glass coverslips as indicated above 
(3.8). During patch-clamp recordings the cells were exposed to an extracellular solution 
containing (in mM): 140 NaCl, 1 CaCl2, 2 MgCl2, 2.8 KCl, 10 HEPES-NaOH and 11 
glucose pH 7.2. In some experiments, we used DVF extracellular solution described 
previously (3.8.1). For assessment of cation permeation profiles of TRPM6 and 
TRPM7, the external solutions contained 10 mM HEPES-NaOH, 260 mM mannitole 
and 10 mM of individual divalent cations (ZnCl2, MgCl2, or CaCl2). The divalent-based 
solutions were adjusted to pH 7.0 (to prevent the precipitation of ZnCl2) using N-methyl-
D-glucamine (NMDG). 
The standard Mg2+-free intracellular pipette solution was identical to experiments with 
TS cells (3.8.2). A nominally Mg2+-free intracellular solution contained (in mM) 140 Cs-
glutamate, 8 NaCl and 10 HEPES-CsOH. A pipette solution with 1 µM free [Mg2+]i 
comprised (in mM): 140 Cs-glutamate, 8 NaCl, 0.0016 MgCl2, 10 Cs-EGTA and 10 
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HEPES-CsOH. A pipette solution with 2 mM free [Mg2+]i contained (in mM): 120 Cs-
glutamate, 8 NaCl, 2 Cs-EDTA, 10 HEPES-CsOH and 4 mM MgCl2. A pipette solution 
with 210 µM [Mg·ATP]i and 10 µM free [Mg
2+]i contained (in mM): 140 Cs-glutamate, 8 
NaCl, 3 Cs-EDTA, 10 HEPES-CsOH and 2.5 mM Mg·ATP. 
For the assessment of Mg2+ concentration-response of recombinant TRPM6 and 
TRPM7, the intracellular pipette solution contained of (in mM): 120 (or 140) Cs-
glutamate, 8 NaCl, 10 Cs-EGTA, 10 HEPES-CsOH and different amount of MgCl2 
(Table 3.5). To study Mg·ATP concentration-response, we used the following 
intracellular solution (in mM): 120 (or 140) Cs-glutamate, 8 NaCl, 10 Cs-EGTA, 3 Cs-
EDTA, 10 HEPES-CsOH, and different amount of Mg·ATP and MgCl2 as outlined in 
Table 3.6. The internal solutions were adjusted to pH 7.2 and 290 mOsm. 
 
Table 3.5. Internal solution used to study Mg
2+
 concentration-response of TRPM6 currents. 
free [Mg
2+
]i 
(mM) 
Cs-
glutamate 
(mM) 
NaCl 
(mM) 
Cs-HEPES 
(mM) 
Cs-EGTA 
(mM) 
MgCl2 
(mM) 
0.1 140 8 10 10 0.16 
0.25 140 8 10 10 0.38 
0.55 140 8 10 10 0.83 
1 140 8 10 10 1.5 
2.3 120 8 10 10 3.4 
5 120 8 10 10 7.1 
 
3.9. Statistical analysis 
Statistical analysis was performed using either Igor Pro or Microsoft Excel. The data 
are shown as means ± standard error of the mean (SEM). We used a two-tailed 
Student’s t-test and statistical significance was accepted at p ≤ 0.05. 
 
 
 
 
 
Methods 
 
 
 
54 
 
Table 3.6. Internal solution used to determine Mg·ATP concentration-response of TRPM6 
currents. 
[Mg·ATP]i 
(mM) 
free 
[Mg
2+
]i 
(µM) 
Cs-
glutam. 
(mM) 
NaCl 
(mM) 
Cs-
HEPES 
(mM) 
Cs-
EGTA 
(mM) 
Cs-
EDTA 
(mM) 
Mg·ATP 
(mM) 
MgCl2 
(mM) 
0 250 140 8 10 10 3 0 0.38 
1.5 250 120 8 10 10 3 2.15 2.71 
3 250 120 8 10 10 3 4.3 2.1 
6 250 120 8 10 10 3 8.55 0.85 
9 250 120 8 10 10 3 12.4 0 
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4. Results 
4.1. Elucidating the role of the endogenous TRPM7 currents in 
cellular Mg2+ uptake 
It has been previously reported by Schmitz et al. [69] and Ryazanova et al. [113] that 
TRPM7 deficient chicken DT40 lymphocytes and mouse embryonic stem cells 
displayed a growth arrest when cultured in a cell culture medium. However, a Mg2+-
supplemented medium rescued the proliferation defect of TRPM7 deficient cells, 
indicating that the TRPM7 channel plays a key role in the cellular Mg2+ homeostasis 
[67, 69, 77, 113, 114, 180]. In contrast, other laboratories suggested that TRPM7 is 
involved in different Ca2+ signaling processes regulating cell motility [88, 115, 116], cell 
proliferation/differentiation/death [67, 69, 109, 114] and mechanosensitivity [116-118]. 
Furthermore, experiments with mouse strains carrying tissue-specific null mutations in 
Trpm7 failed to confirm that TRPM7 is important for Mg2+ homeostasis in the targeted 
tissues [128, 130]. To this end, the cellular function of TRPM7 requires further 
clarification. In the present work, we made use of newly generated experimental 
models, such as mouse trophoblast stem (TS) cells, human haploid leukemia (HAP1) 
cells and primary mouse megakaryocytes (MKs) to elucidate whether the endogenous 
TRPM7 channel is required for Mg2+ metabolism in mammalian cells. 
 
4.1.1. Assessment of TRPM7 function in TS cells 
Placental trophoblasts are extra-embryonic cells playing an indispensable role in the 
prenatal development of mammals. Placental trophoblasts release hormones and 
growth factors regulating the patterning and growth of the embryo. In addition, 
placental trophoblasts directly participate in the transport of nutrients and minerals to 
the fetal blood [192]. 
Recently, our group has shown that TRPM6 activity in placental trophoblasts 
underlines an essential role of Trpm6 in the prenatal development of mice [144]. To this 
end, we reasoned that placental trophoblasts, such as trophoblast stem (TS) cells, can 
be an instrumental model for addressing the cellular functions of the kinase-coupled 
TRPM6 and TRPM7 channels. TS cells can be isolated from mouse blastocysts. These 
cells have the capability to proliferate indefinitely in the presence of specific growth 
factors in the culture medium. TS cells are able to differentiate in vitro into the various 
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placental trophoblasts forming the fetal portion of the placenta [183, 184]. Finally, TS 
cells are well suited for examining the transport functions of placental trophoblasts 
[179, 183]. 
 
 
 
 
 
 
Figure 4.1. Breeding strategy used to generate Trpm7 gene deficient (Trpm7
Δ17/Δ17)
 and 
WT (Trpm7
+/+
) e3.5 blastocysts. Trpm7
Δ17/+
 mice were expected to produce 25% Trpm7
+/+
, 
50% Trpm7
Δ17/+
 and 25% Trpm7
Δ17/Δ17
 blastocysts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Analysis of Trpm7
+/+
 (+/+) and Trpm7
Δ17/Δ17
 (Δ17/Δ17) TS cells. (A) Trpm6 and 
Trpm7 mRNA expression was assessed by RT-PCR approach. RNA extracted from the 
duodenum was employed as a positive control, whereas H2O was used as a negative control. 
GAPDH was probed to show an equal quality of cDNA samples. GeneRuler 100 bp DNA ladder 
was used to estimate the indicated size of PCR products. (B) Western blot analysis of native 
TRPM7 in TS cells. β-Actin was used as a loading control. Spectra multicolor high range protein 
ladder was used to estimate the size of TRPM7 signal. 
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To produce WT and Trpm7 gene deficient TS cells, we isolated embryonic day 3.5 
(e3.5) blastocysts derived from Trpm7Δ17/+ parents as outlined in Fig. 4.1. The 
generated TS clones were propagated and analyzed by PCR of genomic DNA. The 
identified WT and KO clones were subjected to further RT-PCR analysis. These 
experiments confirmed that TS cells co-expressed Trpm6 and Trpm7 transcripts in 
Trpm7+/+ clone, and that Trpm7Δ17/Δ17 cells expressed only Trpm6 transcripts (Fig. 
4.2A). Because of a very low expression level of native TRPM7 protein in mammalian 
cells, the presence of endogenous TRPM7 protein in Trpm7+/+ and Trpm7Δ17/Δ17 TS 
cells was studied by immunoprecipitation (IP) step with TRPM7-specific antibody 
followed by Western blot analysis of the precipitate using an alternative TRPM7-
specific antibody. These experiments revealed TRPM7 protein (~212 kDa) in WT cells 
(Fig. 4.2B). As expected, Trpm7Δ17/Δ17 TS cells showed no detectable TRPM7 signal 
(Fig. 4.2B). Hence, WT TS cells express TRPM6 and TRPM7 and Trpm7Δ17/Δ17 cells 
are deficient in TRPM7. 
During isolation and initial propagation, we maintained all TS clones in the cell culture 
medium supplemented with 10 mM Mg2+, since Trpm7 deficient cells may require 
additional Mg2+ to proliferate [67, 69]. In these conditions, Trpm7+/+ and Trpm7Δ17/Δ17 TS 
clones displayed the characteristic morphology of TS cells [183]. They formed tight 
colonies with an epithelial sheets-like appearance (Fig. 4.3A). Trpm7+/+ and 
Trpm7Δ17/Δ17 TS cells showed no obvious morphological changes. The clones of both 
genotypes could self-renew during >20 passages. In line with previous studies [183], a 
small fraction of solitary spontaneously differentiated cells were also observed. 
To evaluate whether the growth rate of Trpm7Δ17/Δ17 TS cells is dependent on additional 
Mg2+, we performed the following experiments. Equal amounts of WT and KO TS cells 
were seeded in the medium supplemented with 10 mM MgCl2. After 24 h (day 1), the 
medium was replaced with either the standard medium (containing ~2 mM Mg2+) or the 
Mg2+-supplemented medium (containing additional 10 mM MgCl2). The cells were 
examined after 24, 48 and 72 h (days 2-4). We found that unlike WT cells, Trpm7Δ17/Δ17 
TS cells could not proliferate in the presence of the control medium (Fig. 4.3). 
However, the application of 10 mM Mg2+ rescued the growth defect of Trpm7 deficient 
cells (Fig. 4.3) suggesting that the genetic inactivation of TRPM7 leads to Mg2+ 
depletion and proliferation block of TS cells. 
 
 
 
Results 
 
 
 
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Proliferation rates of 
Trpm7
+/+
 (+/+) and Trpm7
Δ17/Δ17
 
(Δ17/Δ17) TS cells. 1x10
5
 cells/well of 
WT and KO TS cells were seeded in 6-
well plates in TS medium supplemented 
by 10 mM Mg
2+
. After 24 h (day 1), the 
culture medium was replaced either 
with the regular or Mg
2+
-supplemented 
media. (A) Phase-contrast images 
taken at day 3 of the cell culture. (B) 
Growth curves of TS cells. Cell density 
at day 1 was taken as 100%. Data 
represent the mean+/-SEM from three 
independent experiments. t-Test was 
applied for comparison of growth rates 
of Trpm7
+/+
 versus Trpm7
Δ17/Δ17
 cells in 
the regular medium (** p ≤ 0.01; *** p ≤ 
0.001). 
 
So far, no data have been published regarding functional characteristics of the native 
TRPM6 channel. Therefore, we wondered whether it would be possible to detect 
TRPM7-like divalent cation-selective currents in Trpm7 deficient TS cells expressing 
only Trpm6 (Fig. 4.2A). To address this question, we employed patch-clamp technique 
and measured whole-cell currents induced by a Mg2+-free intracellular solution. 
Specifically, WT and KO TS cells were incubated in a physiological extracellular 
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solution containing 3 mM Ca2+ and perfused with a Mg2+-free Cs+-based intracellular 
solution containing Mg2+ chelants, 5 mM EDTA and 10 mM EGTA. These conditions 
are commonly used to activate the native TRPM7 channels as well as to induce the 
recombinant TRPM7 channels in heterologous expression systems [67]. In these 
experiments, Trpm7+/+ TS cells were maintained in culture either in the regular or Mg2+-
supplemented media since supplementary Mg2+ could potentially reduce expression 
levels of TRPM7. As shown on Fig. 4.4, WT cells grown in the Mg2+-supplemented 
medium were capable to develop TRPM7-like divalent cation-selective currents by 
removal of intracellular Mg2+, exhibiting a characteristic current-voltage (I-V) 
relationship of TRPM7 such as a steep rectification, large outward currents and 
relatively small inward currents [67]. Interestingly, WT cells grown in regular medium 
showed significantly increased current amplitudes as compared to cells grown in the 
Mg2+-supplemented medium likely due to down-regulation of TRPM7 expression (Fig. 
4.4). In contrast, KO TS cells completely lacked such TRPM7-like currents (Fig. 4.4), 
suggesting that TRPM6 activity is not measurable in the absence of TRPM7. 
 
 
 
 
 
 
 
Figure 4.4. Divalent cation-selective currents in Trpm7
+/+
 (+/+) and Trpm7
Δ17/Δ17
 (Δ17/Δ17) 
TS cells induced by Mg
2+
-free intracellular solution. (A) Whole-cell currents (mean ± SEM) 
recorded in WT with (n=10) and without (n=15) Mg
2+
 supplementation in the culture medium and 
KO (n=10) TS cells. The currents were extracted at –80 and +80 mV, normalized to cell size 
and plotted versus time of the experiment. (B) Representative current-voltage (I-V) relationships 
extracted from individual ramps at 300 s. (C) Bar graphs of averaged outward (+80 mV, upper 
panel) and inward (–80 mV, lower panel) currents (mean ± SEM) obtained at 300 s (n.s., not 
significant; ** p ≤ 0.01; *** p ≤ 0.001). n, number of cells measured. 
 
Taken together, our findings suggest that TRPM7 plays an indispensable role in Mg2+ 
uptake in TS cells and that its genetic inactivation is associated with Mg2+-dependent 
proliferation defect. This cellular function of TRPM7 in TS cells cannot be maintained 
by TRPM6 alone. Our results indicate only that the endogenous TRPM6 channel is not 
measurable in the absence of TRPM7.  
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4.1.2. Role of TRPM7 in HAP1 cells 
To further verify our findings with TS cells, we investigated a role of TRPM7 in an 
alternative experimental model, human leukemia haploid (HAP1) cells [186-189]. HAP1 
is a near-haploid human cell line that displays a fibroblast-like morphology. This line 
was originally derived from a 39-year-old man with chronic myeloid leukemia (CML) in 
blast crisis. HAP1 cells are positive for the Philadelphia chromosome and express the 
BCR-ABL oncogenic fusion protein. As HAP1 cells only have one copy of each gene, 
CRISPR/Cas9 system allows a quick introduction of loss-of-function mutations in these 
cells. TRPM7 gene deficient HAP1 cells are commercially available (clone 10940–04, 
Horizon genomics, https://www.horizondiscovery.com/). Specifically, CRISPR/Cas9 
was used to introduce a 17-bp deletion in exon 4 of the human TRPM7 gene. 
Accordingly, we studied whether this new experimental model could be instrumental for 
addressing a role of the endogenous TRPM7 in hematopoietic cells. 
To confirm that the KO clone carries a loss-of-function mutation in TRPM7, we 
conducted RT-PCR followed by sequencing of the obtained PCR product. We used 
PCR primers flanking exon 4 of the gene. In WT HAP1 cells, we obtained a single PCR 
product at expected molecular weight, whereas in KO cells we could amplify two 
products as illustrated in Fig. 4.5A. The sequencing of these amplicons demonstrated 
that KO cells express two alternatively spliced TRPM7 transcripts with frame-shift 
mutations. Notably, further RT-PCR analysis revealed that WT and KO HAP1 cells 
expressed TRPM6 (Fig. 4.5A). Finally, using Western blot analysis we could show that 
TRPM7 protein was not detectable in KO clone in contrast to WT cells (Fig. 4.5B). 
To examine WT and KO cells functionally, we performed patch-clamp measurements 
of endogenous TRPM7-like currents analogously to experiments conducted with TS 
cells. During recordings, WT and KO HAP1 cells were incubated in a standard 
extracellular solution containing 1 mM Ca2+ and 2 mM Mg2+ and perfused with a Mg2+-
free Cs+-based intracellular solution. As expected, WT cells developed TRPM7-like 
currents (Fig. 4.6). In contrast, KO cells exhibited no detectable TRPM7-like currents 
(Fig. 4.6). We concluded that the 17-bp deletion in exon 4 of the human TRPM7 gene 
results in the loss-of-function mutation. 
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Figure 4.5. Assessment of TRPM7 and TRPM6 expression levels in control (WT) and KO 
HAP1 cells. (A) RT-PCR analysis of mRNA for expression of TRPM6 and TRPM7. RNA 
extracted from HEK 293 cells were used as a positive control and H2O as negative control. 
GAPDH was used to assess RNA quality. GeneRuler 100 bp DNA ladder was used. (B) 
Western blot analysis of native TRPM7 in HAP1 cells. β-Actin was used as a loading control. 
Spectra multicolor high range protein ladder was used. 
 
 
 
 
 
 
 
Figure 4.6. Examination of endogenous TRPM7-like currents in control (WT) and KO 
HAP1 cells. (A) Whole-cell currents (mean ± SEM) recorded in WT (n=9) and KO (n=4) HAP1 
cells. The currents were extracted at –80 and +80 mV, normalized to cell size and plotted 
versus time of the experiment. (B) Representative I-V relationships extracted from individual 
ramps at 300 s. (C) Bar graphs of averaged outward (+80 mV, upper panel) and inward (–80 
mV, lower panel) currents (mean ± SEM) obtained at 300 s (n.s., not significant; *** p ≤ 0.001). 
n, number of cells measured. 
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Next, we evaluated Mg2+ requirements for proliferation of KO HAP1 cells. These 
experiments were performed similarly to studies with TS cells illustrated in Fig. 4.3. WT 
and KO HAP1 cells displayed comparable growth rates in a Mg2+-enriched cell culture 
medium (Fig. 4.7). However, unlike WT cells, KO cells showed a proliferation defect in 
a regular cell culture medium (Fig. 4.7), recapitulating the situation with Trpm7 deficient 
TS cells (Fig. 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Proliferation rates of 
control (WT) and KO HAP1 cells. 
1x10
5
 cells/well of WT and KO HAP1 
cells were seeded in 6-well plates in 
medium supplemented by 10 mM 
Mg
2+
. After 24 h (day 1), the culture 
medium was replaced either with the 
regular or Mg
2+
-supplemented media. 
(A) Images of living WT and KO HAP1 
cells cultured for 3 days. (B) Growth 
rates of WT and KO HAP1 cells. Cell 
density at day 1 was accounted as 
100%. Data represent the mean+/-
SEM from three independent 
experiments. t-Test was applied for 
comparison of growth rates of WT 
versus KO cells in the regular medium 
(*** p ≤ 0.001). 
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Taken together, we concluded that the phenotype of TRPM7 deficient HAP1 cells 
resembles the alterations displayed by Trpm7 KO TS cells, supporting the idea that 
TRPM7 is required for the cellular Mg2+ metabolism. We also noted that, similar to TS 
cells, TRPM6 activity is not detectable in HAP1 cells lacking TRPM7. 
 
4.1.3. Assessment of TRPM7 activity in primary megakaryocytes 
In the next set of experiments, we asked whether our findings with cultured cell lines 
could be replicated in primary cells. To address this question, we exploited 
megakaryocytes (MKs) isolated from a mouse strain with a conditional mutation 
disrupting Trpm7 specifically in MK progenitors. MKs are large bone marrow cells 
responsible for the generation of thrombocytes (platelets) in bone marrow sinusoids 
[180]. Firstly, we generated conditional MK-specific Trpm7 deficient mice by 
intercrossing of Trpm7fl/fl mice with mice carrying the Cre recombinase under the 
platelet factor 4 promoter (Pf4Cre) [180]. Primary MKs were isolated from Trpm7fl/fl 
(control) and Trpm7fl/fl;Pf4cre (MK-specific Trpm7 KO) mice. Remarkably, MK-specific 
Trpm7 KO mice developed macrothrombocytopenia associated with cytoskeletal 
alterations and reduced intracellular Mg2+ concentrations [180]. Also, it was 
demonstrated that the impaired proplatelets formation could be rescued by Mg2+ 
supplementation [180], indicating that deregulated Mg2+ homeostasis may account for 
the impaired proplatelets formation in Trpm7 KO platelets. 
 
 
 
 
 
 
 
 
Figure 4.8. Measurements of native TRPM7-like currents in Trpm7
+/+
 (+/+) and Trpm7
-/-
 (-/-) 
MKs. (A) Whole-cell currents (mean ± SEM) recorded in WT (n=13) and KO (n=11) MKs. The 
currents were extracted at –80 and +80 mV, normalized to cell size and plotted versus time of 
the experiment. (B) Representative I-V relationships extracted from individual ramps at 600 s. 
(C) Bar graphs of averaged outward (+80 mV, upper panel) and inward (–80 mV, lower panel) 
current (mean ± SEM) amplitudes obtained at 600 s (n.s., not significant; * p ≤ 0.05). n, number 
of cells measured. 
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To get a better insight into a mechanistic role of TRPM7 in MKs, we performed patch-
clamp measurements of control and KO MKs using a standard extracellular solution 
containing 3 mM Ca2+ and a Mg2+-free Cs+-based intracellular solution. We observed 
characteristic TRPM7-like currents in control cells but not in KO MKs. Hence, similarly 
to other cell types, the native TRPM7 channel in primary MKs maintains the 
endogenous divalent cation-selective currents controlling Mg2+ metabolism in the cell. 
 
4.2. Contribution of TRPM6 to endogenous divalent cation 
currents 
TRPM6 has been shown to be involved in the regulation of systemic Mg2+ homeostasis 
since loss-of-function mutation of TRPM6 in humans and mice are associated with 
Mg2+ deficiency [68, 70, 71, 77, 79, 142, 144]. However, a functional analysis of the 
recombinant TRPM6 channel resulted in controversial results [68, 77, 92]. Furthermore, 
biophysical characteristics of the native TRPM6 channels have remained unknown so 
far. Hence, in this study we investigated the role of the native TRPM6 channels using 
TS cells. 
 
4.2.1. Functional characterization of Trpm6 gene deficient TS cells 
Because of the high expression of Trpm6 in trophoblasts in the placenta [144], we 
asked whether TS cells could be used to address a role of endogenous TRPM6. As 
shown above (Fig. 4.2A), WT TS cells express both TRPM6 and TRPM7 proteins. 
Trpm7 KO cells expressed only TRPM6 but showed no detectable TRPM7-like currents 
(Fig. 4.4). Accordingly, we thought to generated Trpm6 gene deficient TS cells and 
compare a phenotype of these cells with that of Trpm7 deficient cells. To produce WT 
and Trpm6 gene deficient TS cells, we isolated e3.5 blastocysts from pregnant 
Trpm6βgeo/+ females crossed with Trpm6βgeo/+ males (Fig. 4.9). Genotypes of obtained 
TS clones were determined by PCR approach and only Trpm6+/+ and Trpm6βgeo/βgeo TS 
cells were propagated in the Mg2+-supplemented cell culture medium and further 
examined. First, Trpm6+/+ and Trpm6βgeo/βgeo TS cells were analyzed using RT-PCR. 
Trpm6 transcripts were detected using two independent primer pairs. As expected, WT 
TS cells showed expression of Trpm6 and Trpm7 transcripts (Fig. 4.10A). Moreover, 
RT-PCR confirmed that the mutant cells were devoid of Trpm6 transcripts, while Trpm7 
was expressed in WT and mutant cells (Fig. 4.10A). Second, using Western blot 
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analysis, we could detect the TRPM6 protein (~232 kDa) in Trpm6+/+ TS cells, but not 
in Trpm6βgeo/βgeo TS cells (Fig. 4.10B). 
 
 
 
 
 
 
 
Figure 4.9. Breeding schema used to isolate Trpm6 gene deficient (Trpm6
βgeo/βgeo
) and WT 
(Trpm6
+/+
) e3.5 blastocysts. Heterozygous Trpm6
βgeo/+
 mice were crossed to produce 25% 
Trpm6
+/+
, 50% Trpm6
βgeo/+
 and 25% Trpm6
βgeo/βgeo
 blastocysts. 
 
 
 
 
 
 
 
 
 
Figure 4.10. Assessment of TRPM7 and TRPM6 
expression in Trpm6
+/+
 (+/+) and Trpm6
βgeo/βgeo
 
(βgeo/βgeo) TS cells. (A) Trpm6 and Trpm7 mRNA 
levels in TS cells were determined by RT-PCR 
approach. GeneRuler 100 bp DNA ladder was used. 
(B) Western blot analysis of TRPM6 in TS cells. β-
Actin was used as a loading control. Spectra 
multicolor high range protein ladder was used. 
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Next, in analogy to experiments with Trpm7 deficient TS cells (Fig. 4.3), we 
investigated whether Trpm6 deficient TS cells would require additional Mg2+ in the 
culture medium to proliferate. We observed that Mg2+ supplemented WT and Trpm6 
deficient TS cells grew in tight colonies, characteristic for TS cells (Fig. 4.11A). In 
addition, a small portion of spontaneously differentiated cells were also present. In 
contrast to the situation with Trpm7 deficient cells, we observed that KO TS cells could 
proliferate normally in the presence of physiological Mg2+ levels in the culture medium 
(Fig. 4.11B), indicating that inactivation of TRPM6 did not affect Mg2+ metabolism of 
mutant cells. Therefore, we performed our follow-up experiments with WT and mutant 
cells cultured in a regular cell culture medium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Proliferation rates of Trpm6
+/+
 (+/+) and Trpm6
βgeo/βgeo
 (βgeo/βgeo) TS cells. 
1x10
5
 cells/well of WT and KO TS cells were seeded in 6-well plates in TS medium 
supplemented by 10 mM Mg
2+
. After 24 h (day 1), the culture medium was replaced either with 
the regular or Mg
2+
-supplemented media. (A) Images of living WT and KO TS cells taken after 3 
days of the cell culture. (B) Growth curves of TS cells. Cell density at day 1 was accounted as 
100%. Data represent the mean+/-SEM from three independent experiments.  
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4.2.2. Assessment of native currents in Trpm6 gene deficient TS cells 
We employed patch-clamp technique in the whole-cell configuration to detect 
endogenous currents in Trpm6βgeo/βgeo and Trpm6+/+ TS cells. During recording, the 
cells were maintained in an extracellular solution containing 3 mM Ca2+. Similar to our 
previous experiments (Fig. 4.4), we were able to induce in WT TS cells TRPM7-like 
divalent cation currents by removal of intracellular Mg2+ (Fig. 4.12). We noted that the 
currents in WT and mutant TS cells were developed with similar kinetics (Fig. 4.12A). 
Thus, immediately after establishment of the whole-cell configuration, TRPM7-like 
currents were absent, but they were gradually increased and reached a plateau after 
~300 s of the measurements (Fig. 4.12A). We observed that TS cells of both 
genotypes displayed a similar TRPM7-like shape of I-V relationships (Fig. 4.12B). 
However, the outward currents measured at +80 mV in Trpm6βgeo/βgeo cells displayed 
significantly lower current amplitudes as compared to WT cells (Fig. 4.12C). 
 
 
 
 
 
 
 
 
Figure 4.12. Divalent cation-selective currents in Trpm6
+/+
 (+/+) and Trpm6
βgeo/βgeo
 
(βgeo/βgeo) TS cells induced by Mg
2+
-free intracellular solution. (A) Whole-cell currents 
(mean ± SEM) recorded in WT (n=22) and KO (n=22) TS cells. The currents were extracted at  
–80 and +80 mV, normalized to cell size and plotted versus time of the experiment. (B) 
Representative I-V relationships extracted from individual ramps at 400 s. (C) Bar graphs of 
averaged outward (+80 mV, upper panel) and inward (–80 mV, lower panel) current amplitudes 
(mean ± SEM) obtained at 400 s (n.s., not significant; *** p ≤ 0.001). n, number of cells 
measured. 
 
It is well documented [67, 72, 193] that extracellular divalent cations (Mg2+ and Ca2+) 
act as a permeant blocker of the TRPM7 channel, resulting in very small inward 
currents at physiological membrane potentials ranging in mammalian cells from –40 
mV to –80 mV. Accordingly, it is difficult to compare inward currents measured in WT 
versus KO TS cells (Fig. 4.12A). However, exposure of TRPM7 to divalent cation-free 
(DVF) external solution relieves the channel from the block resulting in a fast induction 
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of large inward currents at negative membrane potentials [67, 69]. Therefore, we used 
such experimental setting in our study (Fig. 4.13). We induced TRPM7-like currents 
using the standard intracellular solution and an external solution containing 1 mM Ca2+ 
and 2 mM Mg2+. When TRPM7-like currents were fully induced (at ~500s), cells were 
exposed to DVF solution (Fig. 4.13A-C), which caused induction of large and linear 
inward currents carried by monovalent cations. In line with our previous measurements 
(Fig. 4.12), we found that Trpm6 deficient cells exhibited significantly reduced inward 
and outward currents at these experimental conditions (Fig. 4.13D). 
Taken together, we concluded that, unlike to Trpm7, inactivation of Trpm6 caused a 
reduction of divalent cation-selective currents in TS cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Divalent cation-selective currents in Trpm6
+/+
 (+/+) and Trpm6
βgeo/βgeo
 
(βgeo/βgeo) TS cells measured at DVF conditions. (A) Whole-cell currents (mean ± SEM) 
recorded in WT (n=16) and KO (n=14) TS cells. When currents were fully activated, the cells 
were perfused with a DVF solution as indicated by the black bars. The currents were extracted 
at –80 and +80 mV, normalized to cell size and plotted versus time of the experiment. (B) A 
magnification of currents shown in (A). (C) Representative I-V relationships obtained from 
individual ramps before (400 s) and during DVF application. (D) Bar graphs of averaged 
outward (+80 mV, upper panel) and inward (–80 mV, lower panel) current amplitudes (mean ± 
SEM) obtained before (filled bars) and during (open bars) exposure to DVF (n.s., not significant; 
* p ≤ 0.05; ** p ≤ 0.01). n, number of cells measured. 
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4.2.3. Effects of cytosolic Mg2+ and Mg·ATP on currents in WT and Trpm6 
deficient TS cells 
It is well known that the currents mediated by TRPM7 are inhibited by intracellular free 
Mg2+ ([Mg2+]i) and Mg·ATP ([Mg·ATP]i) [67, 69, 95]. Consequently, it was suggested 
that these inhibitory effects underline a physiological negative feedback on TRPM6 and 
TRPM7 activity enabling to adjust influx of Mg2+ according to cellular contents of Mg2+ 
and Mg·ATP. Therefore, we investigated concentration-response of TRPM7-like 
currents to [Mg2+]i in Trpm6
βgeo/βgeo and Trpm6+/+ TS cells. We used Cs+-based pipette 
solutions containing different levels of free Mg2+ (Table 3.3). As shown in Fig. 4.14A, 
increasing [Mg2+]i caused a concentration-dependent inhibition of TRPM7-like currents 
in TS cells of both genotypes. The currents were fully inhibited by [Mg2+]i beyond 2 mM. 
The half-maximal inhibitory concentration (IC50) calculated from these datasets was 
584 µM for KO and 482 µM for WT TS cells, suggesting that physiological levels of 
cytosolic Mg2+ concentrations (0.5-1 mM [93, 94]) regulate TRPM7-like currents 
similarly in Trpm6βgeo/βgeo and Trpm6+/+ cells. 
 
 
 
 
 
 
 
 
Figure 4.14. Concentration-dependent inhibition of whole-cell currents by intracellular 
Mg
2+
 (A) and Mg·ATP (B) in Trpm6
+/+
 (+/+) and Trpm6
βgeo/βgeo
 (βgeo/βgeo) TS cells. Mean 
current amplitudes assessed at +80 mV and extracted at 400 s were used to fit the curves and 
calculate the indicated IC50 values (4-18 cells per concentration). Error bars indicate SEM. 
 
Next, we investigated effects of Mg·ATP on TRPM7-like currents in Trpm6βgeo/βgeo and 
Trpm6+/+ TS cells. To determine concentration-response of TRPM7-like currents to 
[Mg·ATP]i, we used a Cs
+-based intracellular solutions containing 2.7 mM EDTA, and 
different amount of Mg·ATP and MgCl2 to achieve the desired Mg·ATP concentrations 
(Table 3.4). Internal free Mg2+ was set to 250 µM at all concentrations of Mg·ATP 
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examined. As expected, TRPM7-like currents were suppressed by [Mg·ATP]i (Fig. 
4.14B). Unlike to experiments with [Mg2+]i, we observed a leftward shift in 
concentration-dependent suppression of the currents in Trpm6 deficient cells by 
[Mg·ATP]i. The calculated IC50 for Trpm6 deficient and WT TS cells was 1.6 mM and 
2.9 mM, respectively (Fig. 4.14B). These results suggested that TRPM6 alters the 
sensitivity of TRPM7-like currents to Mg·ATP but not to Mg2+. 
 
4.2.4. Assessment of constitutive channel activity in WT and Trpm6 
deficient TS cells 
Currents conducted by the recombinant or native TRPM7 channels are usually not 
detectable immediately after break-in of the cell membrane by a patch microelectrode 
(i.e., upon establishment of the whole-cell configuration), but start to develop within a 
few seconds following depletion of intracellular Mg2+. However, we noted that ~30% 
WT TS cells exhibited large TRPM7-like currents immediately after breaking of the cell 
membrane. I-V relationships of these pre-activated or constitutively active currents 
were indistinguishable from the shape of I-V characteristic of fully developed TRPM7-
like currents. Typical examples of induced (dashed line) versus constitutively active 
(straight line) currents are illustrated in Fig. 4.15A. We also noted that Trpm6 deficient 
cells display a lower number of cells with such pre-activated TRPM7-like currents. In 
order to quantify these findings in WT and mutant cells, we set up formal criteria to 
exclude from further analysis measurements contaminated by high background 
currents, which were unlikely conducted by TRPM6 or TRPM7. First, we excluded 
measurements if series resistance (Rs) was more than 10 MΩ for at least 15 ramps. 
Second, we considered that pre-activated TRPM7-like currents should have the 
characteristic pronounced rectification of its I-V relationship at positive membrane 
potentials and small inward currents at negative membrane potentials, i.e., current 
amplitudes at –90 mV have to be 5 times smaller than at +90 mV. Finally, we 
considered that the cell exhibited pre-activated TRPM7-like currents if current 
amplitudes more than 60 pA/pF (at +80 mV) were observed immediately after the 
break-in of the membrane. 
Using these thresholds, we established that 28.5% of WT TS cells exhibited pre-
activated TRPM7-like currents, whereas only 13.1% of Trpm6 deficient cells showed 
constitutive activity of TRPM7-like channels. Furthermore, we observed that the 
corresponding current amplitudes in mutant cells were significantly smaller than the 
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corresponding values measured in WT cells (Fig. 4.15C). Overall, our findings are 
consistent with the idea that TRPM6 enhances the basal divalent cation-selective 
currents. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. Detection of pre-activated TRPM7-like currents in Trpm6
+/+
 (+/+) and 
Trpm6
βgeo/βgeo
 (βgeo/βgeo) TS cells. (A) Left panel: Representative traces of whole-cell 
currents measured in WT cell displaying pre-activated currents (straight line) as compared to 
WT cell with small initial currents (dashed line). Right panel: Representative I-V relationships of 
currents in Left panel at 1s. (B) Percentage of WT and KO TS cells showed pre-activated 
currents. (C) Bar graphs represent the outward current amplitudes (+80 mV, mean ± SEM) in 
cohorts of WT and KO TS cells displaying pre-activated currents at break-in extracted at 1 s. 
WT (n=91) and KO (n=39) cells (** p ≤ 0.01). n, number of cells measured. 
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4.3. Characterization of recombinant mouse TRPM6 
So far, only the human TRPM6 channel was characterized in heterologous expression 
systems and these experiments produced contradictory observations [68, 77, 82, 91]. 
Therefore, in the second part of the present study, we functionally characterized the 
recombinant mouse TRPM6 channel overexpressed in HEK 293 cells aiming to clarify 
whether its functional characteristics could help to explain the role of the native TRPM6 
in TS cells. 
 
4.3.1. Heterologous expression of mouse TRPM6 cDNA in HEK 293 cells 
Using molecular biology techniques, a full-length mouse TRPM6 cDNA has been 
cloned in our laboratory from RNA isolated from the mouse lung tissue [181]. The 
obtained TRPM6 cDNA encodes a 2028 aa protein containing a highly conserved in 
TRPM channels N-terminal domain followed by a channel segment and a C-terminal 
kinase domain (Fig. 1.3B). Based on experiments with TRPM7 [194], we could predict 
locations of residues essential for a catalytic activity of the TRPM6 kinase, for instance, 
K1810 (K1646 in mouse TRPM7 protein) [69, 195] and a threonine residue (T1730) 
autophosphorylated by the TRPM6 kinase domain (corresponding to S1567 in the 
mouse TRPM7 channel [86]) (Fig. 4.16A). 
To examine these predictions, we used site-directed mutagenesis to generate a 
TRPM6 cDNA version containing a ‘kinase-dead’ (KD) mutation (TRPM6K1810R) and a 
variant lacking the predicted phosphorylation residue (TRPM6T1730A). Next, we 
transiently transfected HEK 293 cells with WT TRPM6, TRPM6K1810R and TRPM6T1730A 
constructs and assessed expression levels of the TRPM6 variants by Western blot 
using a rabbit polyclonal antibody specific for phosphorylated T1730 in TRPM6 
((p)T1730-specific antibody) and a commercially available anti-TRPM6 polyclonal 
antibodies (ab47017) to detect total TRPM6 content (Fig. 4.16B). We observed that 
ab47017 detected similar levels of 232 kDa WT TRPM6, TRPM6K1810R and 
TRPM6T1730A, whereas (p)T1730-specific antibody could detect only WT version of 
TRPM6 (Fig. 4.16B). These results indicate that the kinase domain of TRPM6 
phosphorylates T1730 and that KD mutation blocks the kinase activity of TRPM6. 
Hence, heterologous expression of mouse TRPM6 cDNA constructs allowed us to 
express the full-length TRPM6 with the active kinase. 
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Figure 4.16. Assessment of the mouse TRPM6 kinase activity. (A) Kinase domain of the 
mouse TRPM6 protein. K1810 is a conserved residue of the catalytic site of the kinase domain. 
T1730 is a residue phosphorylated by the TRPM6 kinase. (B) Western blot analysis of WT and 
mutant TRPM6 expression constructs using the anti-(p)T1730 antibody. Western blot was 
repeated 3 times with analogous results. 
 
4.3.2. Patch-clamp analysis of HEK 293 cells expressing mouse TRPM6 
For assessment of TRPM6 mediated currents, HEK 293 cells were transiently 
transfected with 2 µg mouse TRPM6 or TRPM7 cDNA placed in pIRES2-EGFP 
plasmid, which enables to express simultaneously TRPM6 or TRPM7 and the 
enhanced green fluorescent protein (EGFP). Consequently, only EGFP-positive cells 
were studied in the patch-clamp experiments. Likewise to experiments with TS and 
HAP1 cells, the whole-cell currents were elicited by a voltage ramps from –80 to +80 
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mV, using the standard external solution containing 2 mM Mg2+ and 1 mM Ca2+ and the 
standard Mg2+-free internal solution. 
In a good agreement with previous studies [66, 67], characteristic TRPM7 currents 
were small immediately after establishment of the whole-cell configuration, however, 
they were quickly increased because of removal of internal Mg2+ and were fully 
developed at ~100 s (Fig. 4.17A). TRPM6-expressing cells also displayed currents 
(Fig. 4.17A,B). Like TRPM7, TRPM6 currents were very small after break-in and fully 
developed after ~100s of recordings (Fig. 4.17A,B). However, TRPM6 exhibited some 
features well distinguishable from TRPM7. Firstly, TRPM6 current amplitudes were ~3-
fold smaller (Fig. 4.17A,D). Secondly, TRPM6 currents were gradually suppressed after 
~120s of recordings (Fig. 4.17B). Further analysis showed that TRPM6 displayed a 
TRPM7-like steeply outwardly rectifying I-V relationship (Fig. 4.17C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. Assessment of mouse TRPM6 and TRPM7 currents in HEK 293 cells. (A) 
Whole-cell currents (mean ± SEM) measured in TRPM6 (red), TRPM7 transfected (blue) and 
untransfected (black) cells (n = number of cells measured). The current amplitudes were 
acquired at –80 and +80 mV, normalized to cell size and plotted versus time of the experiment. 
(B) A magnification of TRPM6 and endogenous currents shown in (A). (C) Representative I-V 
relationships of currents shown in (A) extracted from individual ramps at 90s. (D) Bar graphs of 
averaged outward (+80 mV, upper panel) and inward (–80 mV, lower panel) currents (mean ± 
SEM) obtained at 90 s (** p ≤ 0.01; *** p ≤ 0.001). 
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It has been demonstrated that endogenous human TRPM7 is expressed in HEK 293 
cells and that the native TRPM7 currents are well detectable in this cell line [67]. In 
fact, we could elicit endogenous TRPM7-like currents in untransfected HEK 293 cells 
(Fig. 4.17 A,B). However, these endogenous currents were not detectable immediately 
upon establishment of the whole-cell configuration, developed over a longer time 
period, and were ~10-fold smaller as compared to TRPM6 currents (Fig. 4.17 B,D). 
Hence, the endogenous TRPM7 channels could not contribute or significantly 
contaminate our recordings with TRPM6-expressing cells. 
Next, we studied whether the recombinant TRPM6 channel activity could be 
functionally expressed in TS cells deficient in TRPM7. TRPM7 KO TS cells were 
electroporated with mouse TRPM6 cDNA and the patch-clamp measurements were 
performed 24 h after transfection. These measurements revealed whole-cell currents 
highly resembling TRPM6 currents observed in transfected HEK 293 cells (Fig. 4.18). 
Thus, transfection of different cell types with mouse TRPM6 cDNA allowed us to 
measure the TRPM6 channel activity. 
 
 
 
 
 
 
 
Figure 4.18. Expression of mouse TRPM6 in TS cells. Trpm7 gene deficient TS cells were 
electroporated with TRPM6 cDNA and examined by patch-clamp technique. (A) Whole-cell 
currents (mean ± SEM) measured in TRPM6-expressing (red) and untransfected (black) TS 
cells (n = number of cells measured). The current amplitudes were acquired at –80 and +80 
mV, normalized to cell size and plotted versus time of the experiment. (B) Representative I-V 
relationships of the currents shown in (A) extracted from individual ramps at 90 s. 
 
Zhang et al. [92] reported that transient overexpression of human TRPM6 cDNA 
enabled to produce a functional channel only if cDNA was inserted in a pCINeo-IRES-
GFP expression vector. However, the same TRPM6 cDNA placed in several other 
plasmids could not produce functional channels [92]. This unexpected characteristic of 
human TRPM6 cDNA seems to be unique among known ion channels and remains to 
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be explained mechanistically. Therefore, we investigated whether functional expression 
of our mouse TRPM6 clone is also affected by plasmid backbone. We sub-cloned 
TRPM6 cDNA into a widely used pcDNA3.1 vector [77] and co-transfected this 
construct with a small amount of EGFP cDNA (pcDNA3.1) in HEK 293 cells. Patch-
clamp measurements of EGFP-positive HEK 293 cells (Fig. 4.19) detected inward and 
outward currents recapitulating TRPM6 currents measured in HEK 293 cells 
transfected with pIRES2-EGFP-TRPM6 construct (Fig. 4.17). We concluded that the 
expression vectors are interchangeable for functional expression of mouse TRPM6 
cDNA. Therefore, in our follow-up experiments we used only pIRES2-EGFP-TRPM6 
vector. 
Taken together, our results indicate that overexpression of the mouse TRPM6 protein 
results in formation of functional homomultimeric channel complexes with a moderate 
channels activity as compared to the recombinant TRPM7 channels. 
 
 
 
 
 
 
 
 
Figure 4.19. Evaluation of HEK 293 cells transfected with mouse TRPM6 cDNA inserted in 
pcDNA3.1 vector. TRPM6 cDNA in pcDNA3.1 was co-transfected with EGFP construct 
(pcDNA3.1) in HEK 293 cells. (A) Whole-cell currents (mean ± SEM) measured in EGFP-
positive cells (n = number of cells measured). The current amplitudes were acquired at –80 
(lower traces) and +80 mV (upper traces), normalized to cell size and plotted versus time of the 
experiment. (B) Representative I-V relationships of the currents shown in (A) extracted from 
individual ramps at 70 s. 
 
4.3.3. Cation permeability of the mouse TRPM6 channel 
TRPM7 has been characterized as a cation channel selective for divalent cations 
including Ca2+, Mg2+ and Zn2+ [67, 72]. To assess the cation permeation profile of 
mouse TRPM6, we examined a so-called divalent cation’s permeation block of TRPM6 
currents, a well-described channel characteristic of TRPM7. To this end, HEK 293 cells 
were transiently transfected with TRPM6 or TRPM7 cDNAs. Subsequently, EGFP-
positive cells were induced by the standard Mg2+-free intracellular solution. After a full 
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development of the currents, the cells were exposed to a divalent cation-free (DVF) 
external solution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Assessment of mouse TRPM6 and TRPM7 currents in DVF extracellular 
solution. Left panels: Whole-cell currents (mean ± SEM) measured in TRPM7 transfected (A), 
untransfected (B) and TRPM6 transfected (C) HEK 293 cells (n = number of cells measured). 
Currents were induced using the standard free [Mg
2+
]i intracellular solution and the standard 
external solution. When currents were fully developed, cells were perfused with the DVF 
solution. The current amplitudes were acquired at –80 and +80 mV, normalized to cell size and 
plotted versus time of the experiment. Right panels: Representative I-V relationships obtained 
from individual ramps before (blue), during (red) and after (green) DVF application as indicated 
in the left panels by coloured data points. 
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In line to other studies [67], exposure of TRPM7-expressing cells to DVF solution could 
abolish the permeation block of the channel and, consequently, entailed large 
monovalent cation currents with characteristic linear I-V relationships (Fig. 4.20A). 
These linearized monovalent currents were stable over exposure time. However, these 
alterations were fully reversed after wash-out of DVF solution (Fig. 4.20A). Native 
TRPM7 currents showed a similar response to application of DVF saline (Fig. 4.20B). 
In contrast to TRPM7, TRPM6 transfected cells showed only initial response to the 
application of DVF solution characterized by transient increases of both outward and 
inward currents followed by a fast and irreversible inactivation of TRPM6 activity (Fig. 
4.20C). Mechanisms underlying such fast inactivation of TRPM6 currents remain 
unclear and should be elucidated in the future. Thus, unlike to TRPM7, mouse TRPM6 
is capable of developing monovalent currents only for a short time. 
Next, we conducted experiments aiming to assess the relative divalent cation 
permeation profiles of TRPM6 in comparison to TRPM7. To determine the cation 
selectivity of TRPM7, two approaches were previously used: (i) by a comparison of 
reversal potentials of monovalent currents before and after application of external 
solutions containing distinct divalent cations [67, 72, 191], and (ii) by assessment of 
inward current amplitudes in cells exposed to external solutions containing individual 
divalent cations [67, 72, 191]. Since assessment of the reversal potential of monovalent 
TRPM6 currents was impossible (Fig. 4.20C), we focused on the second option (Fig. 
4.21, 4.22). Whole-cell currents were induced in either TRPM6 or TRPM7 transfected 
HEK 293 cells using the standard internal and external solutions. When currents were 
developed, the cells were transiently exposed to a saline containing 10 mM of Zn2+, 
Ca2+ or Mg2+ and amplitudes of inward currents at –80 mV were estimated. We tested 
10 mM solutions since Zn2+ is poorly soluble above 10 mM at pH 7.0. To prevent a 
contamination of recordings by Na+ currents, external monovalent cations were 
replaced by non-permeant N-methyl-D-glucamine (NMDG). Finally, in order to offset 
variations in expression levels of TRPM6 and TRPM7, we normalized outward and 
inward currents (current amplitudes immediately before the application of divalent 
cation-based solutions were set to “1”). Our experiments revealed that the exposure of 
TRPM7 transfected cells to 10 mM Zn2+ led to a ~3-fold increase of inward currents 
(Fig. 4.21A). The perfusion of cells with 10 mM Mg2+ or 10 mM Ca2+ caused a 
moderate but statistically significant reduction of inward currents likely due to a 
negative effect of these cations on the channel gating (Fig. 4.21B,C). Thus, in 
accordance with published work [72], TRPM7 showed a higher permeability for Zn2+ in 
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comparison to Mg2+ and Ca2+. In addition, TRPM7 showed an equal permeability for 
Mg2+ and Ca2+. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21. Assessment of divalent cation permeability of mouse TRPM7. Left panels: 
Whole-cell currents measured in TRPM7 transfected HEK 293 cells (n = number of cells 
measured). When currents were fully activated, the cells were exposed to an external solution 
containing 10 mM Zn
2+
 (A), 10 mM Mg
2+
 (B) or 10 mM Ca
2+
 (C). The currents were acquired at 
–80 (lower traces) and +80 mV (upper traces), normalized to cell size and plotted versus time of 
the experiment. Current amplitudes immediately before the application of the divalent cation-
based solutions (Imax) were set to “1” and normalized current amplitudes (I/Imax ± SEM) were 
calculated. Middle panels: Representative I-V relationships obtained from individual ramps 
before (blue) and during (red) application of the divalent cation as indicated in the left panels. 
Right panels: Bar graphs of averaged inward currents (–80 mV, I/Imax ± SEM) obtained before 
(blue) and during (red) application of the divalent cation-based solutions as indicated in the left 
panels by coloured data points (* p ≤ 0.05, *** p ≤ 0.001). 
 
 
Results 
 
 
 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22. Assessment of divalent cation permeability of mouse TRPM6. Left panels: 
Whole-cell currents measured in TRPM6 transfected HEK 293 cells (n = number of cells 
measured). When currents were fully activated, the cells were exposed to an external solution 
containing 10 mM Zn
2+
 (A), 10 mM Mg
2+
 (B) or 10 mM Ca
2+
 (C). The currents were acquired at 
–80 and +80 mV, normalized to cell size and plotted versus time of the experiment. Current 
amplitudes immediately before the application of the divalent cation-based solutions (Imax) 
were set to “1” and normalized current amplitudes (I/Imax ± SEM) were calculated. Middle 
panels: Representative I-V relationships obtained from individual ramps before (blue) and 
during (red) application of the divalent cation as indicated in the left panels. Right panels: Bar 
graphs of averaged inward currents (–80 mV, I/Imax ± SEM) obtained before (blue) and during 
(red) application of the divalent cation as indicated in the left panels by coloured data points 
(n.s., not significant; ** p ≤ 0.01, *** p ≤ 0.001). 
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Next, we performed a similar assessment of TRPM6 currents. Like TRPM7, TRPM6 
was found to be well permeable for Zn2+, since the application of 10 mM Zn2+ caused a 
~2-fold increase of inward currents (Fig. 4.22A). In contrast to TRPM7, inward currents 
of TRPM6 were increased in the presence of 10 mM Mg2+ (Fig. 4.22B) and were 
invariable by exposure of the cells to 10 mM Ca2+ (Fig. 4.22C). These results 
suggested that TRPM6 is more selective to Mg2+ as compared to Ca2+. To summarize, 
we found that TRPM6 channel is highly permeable for divalent cations. However, the 
ion selectivity profile of TRPM6 is not identical to that of TRPM7. 
 
4.3.4. The mouse TRPM6 channel is highly sensitive to intracellular Mg2+ 
As mentioned above (4.2.3), it has been proposed that [Mg2+]i and [Mg·ATP]i are 
endogenous regulators of TRPM7 and TRPM6 [67-69, 92, 95, 100]. To access the 
sensitivity of TRPM6 to [Mg2+]i, we attempted to compare a concentration-dependent 
response of TRPM6 versus TRPM7 currents using internal solutions containing 
different levels of free Mg2+. In our initial experiments, we examined TRPM6 and 
TRPM7 transfected HEK 293 cells using either the standard Mg2+-free intracellular 
pipette solution or a solution containing 1 µM free [Mg2+]i (Fig. 4.23). In line with 
previous work [67, 69, 95], we observed that 1 µM free [Mg2+]i did not elicit an inhibitory 
effect on TRPM7 (Fig. 4.23A,F) and caused only a minor suppression of endogenous 
TRPM7 currents in untransfected HEK 293 cells (Fig. 4.23B,F). Surprisingly, we found 
that the currents in TRPM6 transfected cells were not activated at all in the presence of 
1 µM free [Mg2+]i (Fig. 4.23C,F). Next, we attempted to perfuse TRPM6-expressing 
cells with a nominally Mg2+-free intracellular solution (n.f), i.e., a standard Cs-based 
Mg2+-free internal solution lacking divalent chelators EDTA or EGTA. As demonstrated 
in Fig. 4.23D, TRPM6 currents could not be induced as well in these conditions.  
It has been suggested that the catalytic activity of the TRPM7 kinase regulates the 
sensitivity of TRPM7 to Mg2+ and Mg·ATP [69, 95]. Therefore, using ‘kinase-dead’ 
TRPM6K1810R version, we studied whether the kinase activity of TRPM6 interfered with 
the high sensitivity of TRPM6 to [Mg2+]i. However, our experiments showed that, like 
TRPM6, TRPM6K1810R is inactive in the presence of 1 µM free [Mg2+]i, but could be 
activated with the standard Mg2+-free solution (Fig. 4.23E,F). 
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Figure 4.23. Effects of intracellular Mg
2+
 on mouse TRPM6 and TRPM7 currents. (A-C) 
Whole-cell currents (mean ± SEM) measured in TRPM7 transfected (A), untransfected (B), or 
WT TRPM6 transfected (C) HEK 293 cells (n = number of cells measured). Cells were perfused 
either with the standard Mg
2+
-free intracellular solution (filled circles) or with a solution 
containing 1 µM free [Mg
2+
]i (open circles). The currents were acquired at –80 and +80 mV, 
normalized to cell size and plotted versus time of the experiment. (D) Measurements were 
performed with TRPM6 transfected cells as in (C) except that the nominally free [Mg
2+
]i solution 
(n.f.) was used. (E) Measurements were performed with TRPM6
K1810R
 as in (C). (F) Bar graphs 
of averaged outward currents (+80 mV, mean ± SEM) shown in (A-E). Current amplitudes were 
extracted at time intervals when the currents were maximally induced by the Mg
2+
-free 
intracellular solution as follows: at 200s for TRPM7 (blue) and untransfected cells (black), 50s 
for WT TRPM6 (red), 80 s for TRPM6
K1810R
 (green) (n.s., not significant; * p ≤ 0.05; ** p ≤ 0.01). 
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Figure 4.24. Effects of intracellular Mg·ATP on mouse TRPM6 and TRPM7 currents. (A-D) 
Whole-cell currents (mean ± SEM) measured in TRPM7 transfected (A) and untransfected (B) 
HEK 293 cells, or cells transfected either with WT TRPM6 (C) or TRPM6
K1810R
 (D) (n = number 
of cells measured). Cells were perfused either with the standard Mg
2+
-free intracellular solution 
(filled circles) or with a solution containing 210 µM [Mg·ATP]i and 10 µM free [Mg
2+
]i (open 
circles). The currents were acquired at –80 and +80 mV, normalized to cell size and plotted 
versus time of the experiment. (F) Bar graphs of averaged outward currents (+80 mV, mean ± 
SEM) shown in (A-D). Current amplitudes were extracted at time intervals when the currents 
were maximally induced by the Mg
2+
-free intracellular solution as follows: at 200s for TRPM7 
(blue) and untransfected cells (black), 50s for WT TRPM6 (red) and TRPM6
K1810R
 (green) (n.s., 
not significant; ** p < 0.01; *** p < 0.001). 
 
In physiological saline, a Kd of Mg·ATP is ~60 µM (at pH 7.2, 37 
0C). Hence, cytosolic 
levels of Mg·ATP (3-7 mM in most mammalian cells [93, 94]) will be in equilibrium with 
a certain amount of free Mg2+. Consequently, TRPM6 will likely remain inactive in the 
presence of Mg·ATP. To test this idea experimentally, we designed a pipette solution 
with very low content of Mg·ATP (~210 µM) resulting in ~10 µM free Mg2+. Under these 
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conditions, TRPM7 currents were only modestly suppressed by 210 µM Mg·ATP (Fig. 
4.24A,E). Currents mediated by the native TRPM7 channels were also only slightly 
reduced (Fig. 4.24B,E). As expected, both WT TRPM6 and TRPM6K1810R variants were 
inactive in the presence of 210 µM [Mg·ATP]i (Fig. 4.24C,D,E). Thus, TRPM6 revealed 
an exceptionally high sensitivity to cytosolic [Mg2+]i. Interestingly, this notable feature of 
TRPM6 is not dependent on the kinase activity of TRPM6. 
 
4.3.5. Modulation of TRPM6 and TRPM7 by pharmacological compounds 
Recently, our group identified several small synthetic molecules acting as activators or 
inhibitors of the TRPM7 channel [110, 111]. NS8593 was found to be a potent inhibitor 
of TRPM7 [110]. Accordingly, we investigated whether NS8593 could elicit an inhibitory 
effect also on TRPM6. To this end, we activated whole-cell TRPM6 currents by our 
standard approach and applied externally 10 µM NS8593. As TRPM6 currents undergo 
a gradual inactivation stage, a set of untreated cells was also measured to estimate 
better the inhibitory effect of NS8593. We found that 10 µM NS8593 caused a rapid 
inhibition of the TRPM6 channel activity (Fig. 4.25A). 
Next, we examined effects of naltriben [111], a potent agonist of the TRPM7 channel. It 
should be stressed that naltriben cannot exert its effect on TRPM7 if the channel is 
already induced by the Mg2+-free solution. Therefore, we studied the stimulatory effect 
of naltriben on TRPM7 currents using an intracellular solution containing 2 mM free 
[Mg2+]i. As expected, 50 µM naltriben led to a fast activation of TRPM7 currents (Fig. 
4.25B). To investigate a response of TRPM6, we used the standard Mg2+-free 
intracellular pipette solution and the solution containing 1 µM free [Mg2+]i (Fig. 4.25C). 
However, unlike TRPM7, TRPM6 showed no response to 50 µM naltriben. 
2-Aminoethyl diphenylborinate (2-APB) was found to elicit an inhibitory effects on 
TRPM7 currents [91, 108]. It was reported that this compound potentiates the human 
TRPM6 channel [91, 92]. This prompted us to assess the effects of 2-APB on TRPM6 
in comparison to TRPM7. Transiently transfected HEK 293 cells were perfused with the 
standard Mg2+-free intracellular pipette solution and exposed to 200 µM 2-APB when 
TRPM6 and TRPM7 currents reached the maximal amplitudes. In order to offset 
variability in expression levels of TRPM6 and TRPM7 of response to 2-APB, the 
currents were normalized as explained in Fig. 4.21. In good agreement with published 
work [91, 108], 200 µM 2-APB efficiently suppressed TRPM7 currents (Fig. 4.26A). We 
also found that the native TRPM7 currents were only modestly affected by 2-APB (Fig. 
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4.26B). Remarkably, 200 µM 2-APB was able to significantly potentiate TRPM6 
currents in the absence of intracellular Mg2+ (Fig. 4.26C). It was found previously that 1 
µM free Mg2+ is sufficient to suppress TRPM6 (Fig. 4.23C). Therefore, we asked 
whether 200 µM 2-APB was able to counteract the inhibitory effect of Mg2+ on TRPM6. 
As shown in Fig. 4.26D, the increase in TRPM6 currents in the presence of 1 µM free 
Mg2+ was more pronounced. Taken together, our data indicate that TRPM6 and 
TRPM7 have different sensitivity to naltriben and 2-APB. 
 
. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25. Effects of NS8593 and naltriben on mouse TRPM6 currents. (A) Inhibition of 
TRPM6 currents by NS8593. Left panel: Whole-cell currents (mean ± SEM) measured in 
TRPM6 transfected HEK 293 cells (n = number of cells measured). Currents were induced 
using a standard Mg
2+
-free intracellular solution and a standard external solution. When 
currents started to develop, the cells were exposed to 10 µM of NS8593 (open circles). A subset 
of TRPM6-positive cells was examined without application of NS8593 (filled circles). The 
currents were acquired at –80 and +80 mV, normalized to cell size and plotted versus time of 
the experiment. Middle panel: Representative I-V relationships obtained from individual ramps 
before (blue) and during (red and green) application of NS8593 as indicated in the left panel. 
Right panel: Bar graphs of outward currents (+80 mV, mean ± SEM) obtained from untreated 
(green) and NS8593-treated cells (red) as indicated in the left panel (*** p ≤ 0.001). (B) 
Stimulation of TRPM7 currents by naltriben (n = number of cells measured). Currents were 
induced using an intracellular solution containing 2 mM free [Mg
2+
]i and the standard external 
solution. The cells were exposed to 50 µM of naltriben. The currents were acquired at –80 and 
+80 mV, normalized to cell size and plotted versus time of the experiment. (C) Assessment of 
50 µM naltriben effects on TRPM6 currents. Measurements were performed similarly to (B) 
using either the standard Mg
2+
-free intracellular solution (filled circles) or solution containing 1 
µM free [Mg
2+
]i (open circles). 
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Figure 4.26. Effects of 2-APB on mouse TRPM6 and TRPM7 currents. (A, B) Left panels: 
Whole-cell currents measured in TRPM7 transfected (A) and untransfected HEK 293 cells (B)  
(n = number of cells measured). When currents were fully activated, the cells were exposed to 
200 µM 2-APB. The currents were acquired at –80 and +80 mV, normalized to cell size and 
plotted versus time of the experiment, and shown as I/Imax ± SEM. Middle panels: 
Representative I-V relationships obtained from individual ramps before (blue) and during (red) 
application of 2-APB as indicated in the left panels by coloured dots. Right panels: Bar graphs 
of outward currents (+80 mV, I/Imax+/-SEM) obtained from coloured data-points (i.e. blue, red 
or green) as indicated in the left panels (*** p ≤ 0.001). (C, D) Measurements were performed 
with TRPM6 transfected cells similarly to (A) except that a subset of cells were examined 
without application of 200 µM 2-APB (control). Recordings were performed using either the 
standard free [Mg
2+
]i intracellular solution (C) or the solution containing 1 µM free [Mg
2+
]i (D) (* p 
≤ 0.05; ** p ≤ 0.01). 
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Next, we asked whether 2-APB stabilizes TRPM6 monovalent currents which are 
quickly decayed in DVF saline (Fig. 4.20C). To address this question, HEK 293 cells 
expressing TRPM6 were exposed to 200 µM 2-APB in DVF solution. We found that co-
application of 2-APB and DVF allowed to induce large and stable TRPM6 monovalent 
currents with a characteristic linear I-V relationship (Fig. 4.27A). In contrast to mouse 
TRPM6, native TRPM7 currents were reduced in the presence of 2-APB in DFV 
conditions (Fig. 4.27B). Taken together, we concluded that 2-APB positively regulates 
TRPM6 and inhibits TRPM7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27. Effects of 2-APB on mouse TRPM6 in the absence of extracellular divalent 
cations. Left panels: whole-cell currents measured in TRPM6 transfected (A) and untransfected 
(B) HEK 293 cells (n = number of cells measured). When currents were fully activated, the cells 
were perfused with DVF solution without (filled circles) or with 2-APB (open circles). The 
currents were acquired at –80 and +80 mV, normalized to cell size and plotted versus time of 
the experiment, and shown as I/Imax ± SEM. Right panels: Representative I-V relationships 
obtained from individual ramps before (blue) and during (red) application as indicated in the left 
panels by coloured dots. 
 
 
Results 
 
 
 
88 
 
4.3.6. Assessment of heteromeric TRPM6/M7 channel complexes 
Our patch-clamp experiments with the recombinant TRPM6 protein suggested that 
overexpressed TRPM6 is able to form homomeric TRPM6 channels, which are 
extremely sensitive to internal Mg2+ and, thereby, will remain inactive in the presence of 
cytosolic free Mg2+ levels (0.5-1 mM in mammalian cells [93, 94]). This finding raises a 
question as how TRPM6 would function in the physiological conditions. It has been 
suggested by our group [77, 79] that the native TRPM6 protein primary exist as a 
subunit of heteromeric channel complexes formed by TRPM6 and TRPM7 
(TRPM6/M7). Accordingly, we asked whether such paradoxical Mg2+ sensitivity of 
TRPM6 could be altered in TRPM6/M7 complexes. To this end, HEK 293 cells were 
co-transfected with 1 µg TRPM6 and 1 µg TRPM7 plasmids. In control experiments, 2 
µg cDNAs were used to transfect the cells. Of note, Western blot analysis revealed that 
co-expression of TRPM6 had no effect on expression levels of TRPM7 (Fig. 4.28). 
Next, we performed patch-clamp experiments with cell expressing only TRPM7 or co-
expressing TRPM6 and TRPM7. We found that TRPM6/M7 transfected cells exhibited 
significantly higher amplitudes compared to cells transfected only with TRPM7 (Fig. 
4.29A). Moreover, it is noteworthy that all cells expressing TRPM6/M7 displayed large 
currents immediately after establishment of the whole-cell configuration (Fig. 4.29B). 
These pre-activated currents showed a characteristic TRPM7-like I-V relationships 
(Fig. 4.29B). In contrast, TRPM7 currents were small after break-in in all measured 
cells (Fig. 4.29B). Further analysis revealed that amplitudes of TRPM6/M7 pre-
activated currents were ~10-fold larger than the corresponding values of TRPM7 (Fig. 
4.29B). Remarkably, such constitutive channel activity was not observed in 
experiments with untransfected HEK 293 cells (Fig. 4.17B) or in the cells transfected 
only with TRPM6 (Fig. 4.17A,B), suggesting that the association of TRPM6 and 
TRPM7 in TRPM6/M7 channel complexes results in a new channel type, which is, 
unlike TRPM6 or TRPM7, constitutively active in resting cells, i.e., in the presence of 
physiological levels of Mg2+ and Mg·ATP. 
Accordingly, in the next set of experiments, we defined the concentration-dependent 
suppression of TRPM6/M7 currents by [Mg2+]i. To address this question, HEK 293 cells 
were transfected by TRPM6/M7 or TRPM7 and examined using internal solutions 
containing different free [Mg2+]i (Table 3.5). As shown in Fig. 4.29C, we observed only 
a minor rightward shift in the concentration-response curve of TRPM6/M7 as compared 
to TRPM7. However, cells expressing TRPM6/M7 exhibited larger current amplitudes 
over the whole range of [Mg2+]i examined (Fig. 4.29C). These results support a notion 
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that TRPM7 offsets the high sensitivity of TRPM6 to Mg2+ in heteromeric TRPM6/M7 
complexes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28. Western blot analysis of HEK 293 cells expressing mouse TRPM6, TRPM7 
and TRPM6/M7. HEK 293 cells were transiently transfected with TRPM6 or/and TRPM7 cDNA 
constructs and cell lysates were studied using either anti-TRPM6 (A) or anti-TRPM7 (B) 
antibodies. Representative blots are shown. The experiment was repeated twice with the similar 
results. 
 
Finally, we asked whether TRPM6/M7 would be active in the presence of Mg·ATP. In 
most mammalian cells, physiological concentrations of intracellular Mg·ATP vary in a 
range of 3-7 mM [93, 94]. In the first experiment, we tested effects of a relatively high 
level of Mg·ATP. We found that 9 mM [Mg·ATP]i caused a nearly full suppression of 
TRPM7 (Fig. 4.30A). Surprisingly, TRPM6/M7 currents were only modestly suppressed 
by 9 mM [Mg·ATP]i (Fig. 4.30A). Similarly to the experiments showed in Fig. 4.29B, 
TRPM6/M7-expressing cells displayed very large currents immediately after break-in 
(Fig. 4.30B).  
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Figure 4.29. Assessment of mouse TRPM6/M7 currents. (A) Left panel: Whole-cell currents 
(mean ± SEM) measured in TRPM7 (blue) and TRPM6/M7 (gray) transfected HEK 293 cells    
(n = number of cells measured). Currents were induced using a standard Mg
2+
-free intracellular 
solution and a standard external solution. The currents were acquired at –80 and +80 mV, 
normalized to cell size and plotted versus time of the experiment. Middle panel: Representative 
I-V relationships of currents illustrated in the left panel extracted from individual ramps at 200s. 
Right panel: Bar graphs of averaged outward currents (+80 mV, mean ± SEM) shown in the left 
panel obtained at 200 s (** p < 0.01). (B) A magnification of currents illustrated in (A). Left 
panel: Outward current amplitudes (+80 mV) acquired from individual cells with the 
corresponding means (dots). Middle panel: Representative I-V relationships of currents 
extracted at 2 s shown in the left panel. Right panel: Bar graphs of averaged outward currents 
(+80 mV, mean ± SEM) shown in the left panel obtained at 2 s (*** p < 0.001). (C) 
Concentration-dependent inhibition of currents by [Mg
2+
]i. Mean current amplitudes assessed at 
+80 mV and extracted at 200 s were used to fit the curves and calculate the indicated IC50 
values (10-12 cells per concentration) (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). Error bars indicate 
SEM. 
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Figure 4.30. Sensitivity of mouse TRPM6/M7 currents to cytosolic Mg·ATP. (A) Left panel: 
Whole-cell currents (mean ± SEM) measured in TRPM7 (blue) and TRPM6/M7 (gray) 
transfected HEK 293 cells (n = number of cells measured). Currents were induced using either 
an internal solution containing 9 mM [Mg·ATP]i and 250 µM free [Mg
2+
]i (open circles) or only 
250 µM free [Mg
2+
]i (filled circles). The currents were acquired at –80 and +80 mV, normalized 
to cell size and plotted versus time of the experiment. Middle panel: Representative I-V 
relationships of currents illustrated in the left panel extracted from individual ramps at 200s. 
Right panel: Bar graphs of averaged outward currents (+80 mV, mean ± SEM) shown in the left 
panel obtained at 200 s (** p < 0.01; *** p < 0.001). (B) A magnification of currents illustrated in 
(A). Left panel: Outward current amplitudes (+80 mV) acquired from individual cells with the 
corresponding means (dots). Middle panel: Representative I-V relationships of currents 
extracted at 2 s shown in the left panel. Right panel: Bar graphs of averaged outward currents 
(+80 mV, mean ± SEM) shown in the left panel obtained at 2 s (*** p < 0.001). (C) 
Concentration-dependent inhibition of currents by [Mg·ATP]i (250 µM free [Mg
2+]i). Mean 
current amplitudes assessed at +80 mV and extracted at 200 s were used to fit the curves and 
calculate the indicated IC50 values (9-12 cells per concentration) (** p ≤ 0.01; *** p ≤ 0.001). 
Error bars indicate SEM. 
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In the second set of experiments, we compared concentration-dependent suppression 
of TRPM6/M7 and TRPM7 currents by [Mg·ATP]i (Table 3.6). Because of experimental 
limitations, effects of [Mg·ATP]i beyond 10 mM could not be reliably examined. We 
found that [Mg·ATP]i caused a suppression of TRPM7 currents with IC50 3.0 mM (Fig. 
4.30C). However, TRPM6/M7 currents showed a remarkably low sensitivity to 
[Mg·ATP]i at all concentrations examined (Fig. 4.30C). Such weak effect of [Mg·ATP]i 
on TRPM6/M7 currents precluded us from a reliable calculation of IC50. Nevertheless, 
fitting of a concentration-response curve suggested that ~15 mM [Mg·ATP]i would 
cause 50% reduction of TRPM6/M7 currents (Fig. 4.30C). Thus, we could conclude 
that physiological levels of [Mg·ATP]i would elicit only a very minor effect on the mouse 
TRPM6/M7 channel complexes. 
The kinase domain of the human TRPM6 is thought to be involved in the regulation of 
Mg·ATP sensitivity of the TRPM6/M7 heteromeric channel complexes [92]. 
Accordingly, we investigated whether the kinase-dead mutation (K1810R) in the mouse 
TRPM6 is able to affect the response of TRPM6 to Mg·ATP. To this end, we co-
transfected HEK 293 cells with TRPM6K1810R and WT TRPM7. Our results 
demonstrated that TRPM6K1810R behaved similar to WT TRPM6 (Fig. 4.31). Thus, our 
data suggested the catalytic activity of the mouse TRPM6 kinase domain is not 
involved in this regulatory mechanism. 
 
  
 
 
 
 
 
 
 
 
Figure 4.31. Assessment of mouse TRPM6
K1810R
 and WT TRPM7. (A) Whole-cell currents 
(mean+/-SEM) recorded in HEK 293 cells co-expressing TRPM6
K1810R
 and WT TRPM7. The 
currents were induced using a standard [Mg
2+
]i free internal solution (filled circles, n=12) and 
solutions containing either 250 µM free [Mg
2+
]i (filled squares, n=11) or 9 mM [Mg·ATP]i and 250 
µM free [Mg
2+
]i (open circles, n=12). The currents were extracted at –80 and +80 mV, 
normalized to cell size and plotted versus time of the experiment. (B) Bar graph of averaged 
outward currents (+80 mV, mean ± SEM) shown in (A) (n.s., not significant; ** p ≤ 0.01). n, 
number of cells measured. 
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5. Discussion 
The kinase-coupled channels TRPM6 and TRPM7 were suggested to play an essential 
role in the organismal Mg2+ balance by regulating Mg2+ influx in the cell [69-71]. 
However, this concept is intensively debated in the scientific literature. For instance, it 
was suggested that TRPM7 regulates different cellular processes in a Mg2+-
independent manner [25]. Functional characteristics of the TRPM6 channel are also 
discussed differently [68, 77, 92]. In the present study, we provide new mechanistic 
evidence supporting the concept that a functional interplay of TRPM6 and TRPM7 
underlines a cellular uptake of Mg2+, what in turn determinates the physiological roles 
of these proteins in organismal Mg2+ homeostasis. 
 
5.1. TRPM7 controls cellular Mg2+ metabolism 
It is commonly accepted that TRPM7 forms a homotetrameric channel, which is 
selective for divalent cations such as Zn2+, Ca2+ and Mg2+. However, there are ongoing 
debates in the literature whether TRPM7-mediated influx of Mg2+ or Ca2+ is relevant for 
the numerous cellular processes regulated by TRPM7. In the pioneering study, Nadler 
et al. used DT40 B cells with a targeted deletion of Trpm7 gene [67]. The homology 
recombination approach allowed an efficient production of clones heterozygous for 
TRPM7 null mutation, but no clones were obtained with loss-of-function mutations in 
both alleles, suggesting that TRPM7 is essential for the cell viability [67]. In follow-up 
experiments, Schmitz et al. have shown that TRPM7 deficient DT40 cells cultured in a 
standard cell culture medium exhibited a profound decreases in total Mg2+ content [69]. 
Moreover, they found that addition of 10 mM Mg2+ (but not Ca2+, Mn2+, or Zn2+) in the 
culture medium allowed these KO cells to grow and proliferate similarly to their parental 
cells, indicating that TRPM7 function is indispensable for the cellular Mg2+ homeostasis 
[69]. The Mg2+-dependent proliferation defect of DT40 B cells could be also rescued by 
ectopic expression of mammalian proteins, which are presumed to function as Mg2+ 
channels or transporters such as SLC41A1 [155, 156], SLC41A2 [157, 158] or MagT1 
[153]. More recently, Ryazanova et al. have demonstrated that Trpm7 gene deficient 
mouse embryonic stem (ES) cells developed a phenotype resembling TRPM7 deficient 
DT40 cells [113], supporting the notion that the ubiquitously expressed TRPM7 channel 
controls Mg2+ uptake in vertebrate cells. However, it has to be stressed that several 
other studies pointed out that TRPM7 functions primarily as Ca2+-permeable channel 
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and, accordingly, that TRPM7 regulates Ca2+-dependent signaling pathways in the cell 
[124, 128, 196-198]. Finally, it was speculated that TRPM7-dependent Zn2+ entry may 
also play a physiological role [106, 199-201]. 
Here, we assessed the cellular role of TRPM7 in three distinct cell types. Specifically, 
we examined consequences of a complete deletion of TRPM7 protein on the 
endogenous TRPM7 currents and the ability of mutant cells to proliferate in a standard 
culture medium or in a medium supplemented with Mg2+. 
Recently, our group has established that the embryonic development of mice is 
critically dependent from TRPM6 activity in placental trophoblasts [144]. Accordingly, 
we asked whether placental cells, such as trophoblast stem (TS) cells, can be used as 
new experimental model to examine the cellular function of the kinase-linked channels. 
To address this question, we produced Trpm7 deficient TS cells from e3.5 blastocysts 
derived from a cross of Trpm7Δ17/+ mice. We found that WT TS cells express TRPM6 
and TRPM7 proteins. Patch-clamp experiments revealed that WT TS cells display 
relatively large divalent cation-selective currents sensitive to intracellular Mg2+. Very 
similar currents were previously measured in many other cell lines and primary isolated 
cells. These currents were referred to as Mg2+-inhibited cation (MIC) currents [97, 98], 
magnesium nucleotide-regulated metal ion (MagNuM) currents [67, 99] or TRPM7-like 
currents [144]. We found that the genetic deletion of Trpm7 in TS cells abrogated 
completely these TRPM7-like currents. We also found that maintaining Trpm7 deficient 
TS cells in a standard cell culture medium leads to suppressed proliferation of these 
KO cells. Furthermore, we demonstrated that viability of KO TS cells can be rescued by 
addition of Mg2+ to the culture medium. These findings support the idea that TRPM7 
currents are essential for the Mg2+ uptake and viability of TS cells [69, 77, 113]. 
To recapitulate our findings with TS cells, we made use of an alternative in vitro model. 
In these experiments, we focused on a functional assessment of haploid human 
leukemia haploid (HAP1) cells [186, 187]. The TRPM7 deficient (KO) clone was 
acquired from Horizon Genomics using CRISPR/Cas9 system [144]. Noteworthy, like 
TS cells, WT HAP1 cells express TRPM6 and TRPM7. WT HAP1 cells harbor 
moderate levels of endogenous TRPM7-like currents. Analogously to TS cells, the 
genetic deletion of TRPM7 completely abolished these currents. As expected, KO 
HAP1 cells could proliferate only if the cell culture medium contained additional Mg2+, 
supporting the concept that TRPM7 plays a vital role in Mg2+ uptake, which is required 
for cell proliferation. Interestingly, similar to the situation with TS cells, this TRPM7 
function could not be compensated by TRPM6. 
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TRPM7 is highly expressed in different types of non-proliferating blood cells [180]. 
Recently, a screen for new inherited forms of macrothrombocytopenia resulted in the 
identification of two human families harbouring loss-of-function point mutations in 
TRPM7 [180]. The affected individuals displayed impaired thrombopoiesis due to 
altered cellular Mg2+ homeostasis and cytoskeletal architecture [180]. We wondered 
whether megakaryocytes (MKs) derived from a mice strain with a conditional 
inactivation of Trpm7 specifically in megakaryocytes can recapitulate alterations 
observed in human MKs of the above-mentioned patients. MKs are large progenitor 
cells in the bone marrow responsible for the generation of blood thrombocytes 
(platelets) [180]. MKs extend long cytoplasmic processes into bone marrow sinusoids, 
called proplatelets, which to release platelets [180]. In a collaboration with Dr. Attila 
Braun’s group, we found that these mutant mice are able to generate MKs and 
platelets in vivo. In our patch-clamp experiments, we could show that mutant MKs 
completely lack native TRPM7 currents. In line with this finding, TRPM7 deficient 
platelets were moderately depleted in Mg2+ [180]. Taken together, we concluded that 
TRPM7 regulates Mg2+ metabolism in this cell type as well. 
To summarize, our experiments with three independent cell types (extraembryonic 
stem cells, tumor-derived cells and non-proliferating cells) support a model that TRPM7 
mediates the endogenous divalent cation-selective currents, which are critically 
implicated in Mg2+ cellular metabolism. 
 
5.2. TRPM6 cooperates with TRPM7 in TS cells 
Mutations in human TRPM6 gene were linked to the familial hypomagnesemia with 
secondary hypocalcemia (HSH), an autosomal recessive disease characterized by low 
Mg2+ and Ca2+ serum levels [70, 71]. However, the first attempt to elucidate 
pathomechanisms of HSH in animal model resulted in unexpected findings. Walder et 
al. [142] found that a constitutive inactivation of Trpm6 results in embryonic death at 
day e12.5. Recently, our group [144] could define a role of Trpm6 in the prenatal 
survival of mice. Our laboratory provided the comprehensive evidence that the 
embryonic mortality of Trpm6 deficient mice is caused by the loss of TRPM6 activity in 
the placental trophoblasts in syncytiotrophoblast layer I (SynT-I) [144]. Accordingly, we 
used a conditional mutagenesis to show that the epiblast-restricted inactivation of 
Trpm6 enables to produce viable adult mice lacking TRPM6 in the whole body [144]. 
We also found that TRPM6 deficiency in the prenatal or adult organisms is associated 
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to systemic Mg2+ deprivation. Taken together, we propose a new model for a role of 
Trpm6 in the prenatal development of mice. According to this model, Trpm6 is required 
for Mg2+ transport via syncytiotrophoblast layers of the placenta. Consequently, the 
genetic inactivation of Trpm6 leads to Mg2+ deficiency and secondary embryonic 
phenotypes such as the growth failure [144]. 
Currently, there is no consensus regarding the cellular function of TRPM6. As already 
mentioned, TRPM6 has been shown to be expressed mainly in the transporting 
epithelial cells of the kidney and intestine [70, 71], whereas TRPM7 is ubiquitously 
expressed [67]. Thus, TRPM6 is always co‐expressed with TRPM7, and it remains to 
be answered why a loss of TRPM6 function in HSH patients and KO mice could not be 
compensated by TRPM7. The critical role of Trpm6 in the placental trophoblasts 
prompted us to use TS cells as an in vitro experimental model to address this question. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. A proposed model representing the role of TRPM6/M7 channels for 
transcellular Mg
2+
 transport in the epithelial cells. Figure modified from [177]. 
 
Analogously to Trpm7 KO TS cells, we derived Trpm6 gene deficient and 
corresponding WT TS cells from Trpm6βgeo/+ parents. In contrast to Trpm7 deficient TS 
cells, TS cells lacking TRPM6 were able to proliferate in standard cell culture medium 
(not fortified by additional Mg2+). Similarly to the previous patch-clamp experiments, our 
analysis of WT TS revealed high density of TRPM7-like currents cells induced by 
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depletion of intracellular Mg2+. However, in contrast to Trpm7 deficient cells 
characterized by a complete lack of the endogenous TRPM7-like currents, we 
observed that Trpm6 deficient cells displayed only a partial reduction of the current 
amplitudes. These findings are fully compatible with a previously suggested model [77, 
144] that native TRPM6 functions as a subunit of heteromeric TRPM6/M7 channel 
complexes (Fig. 5.1). In line with this idea, the deletion of TRPM6 and TRPM7 elicits 
different impacts on the endogenous currents and, consequently, Mg2+-dependent 
proliferation of TS cells: ablation of TRPM7 removes TRPM7 and TRPM6/M7 channel 
complexes, whereas inactivation of TRPM6 impairs only TRPM6/M7 channels. 
Based on such assumption, we compared effects of intracellular Mg2+ and Mg·ATP on 
currents in TRPM6 KO cells (expressing only TRPM7 channels) versus WT cells 
(containing TRPM7 and TRPM6/M7 channels). As mentioned above, Mg2+ and 
Mg·ATP were suggested as physiological regulators of TRPM6 and TRPM7 [67-69, 92, 
95, 100]. We found that TRPM7-like currents were similarly inhibited by Mg2+ in TS 
cells of the both genotypes, i.e., TRPM7 and TRPM6/M7 channels likely display the 
similar sensitivity to intracellular Mg2+. However, we observed that the currents in 
Trpm6 deficient cells were substantially more sensitive to Mg·ATP as compared to WT 
cells. This finding is consistent with a recent report [92] showing a very low sensitivity 
of recombinant TRPM6/M7 channels overexpressed in HEK 293 cells. We concluded 
that association of native TRPM6 with TRPM7 alters the sensitivity of TRPM6/M7 
channel complexes to Mg·ATP. Consequently, TRPM6/M7 channels will be more 
active in the presence of cytosolic levels of Mg·ATP (Fig. 5.1). Finally, our experiments 
showed that WT TS cells exhibit a significantly higher fraction of cells with spontaneous 
channel activity detectable before a depletion of internal Mg2+ occurs. Such high 
constitutive activity of the endogenous TRPM7-like currents may be attributed to the 
reduced sensitivity of TRPM6/M7 channels to Mg·ATP in the resting cells (prior to a 
removal of internal Mg2+ by perfusion of cell by the pipette solution). Thus, TRPM6 
alters quantitative and qualitative characteristics of the native TRPM7-like currents 
what will likely enhance entry of Mg2+ in cells co-expressing TRPM6 and TRPM7. 
Apparently, this role of TRPM6 is not essential for cell autonomous functions since 
TRPM7 remains active. However, such an extra Mg2+ entry path may drive a vectored 
transcellular Mg2+ transport (Fig. 5.1). Accordingly, such model is well compatible with 
findings that the in vivo role of TRPM6 cannot be maintained by TRPM7 alone. 
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5.3. Interplay of TRPM6 and TRPM7 channels determines the 
sensitivity of TRPM6/M7 channels to cytosolic Mg2+ and 
Mg·ATP 
In the next step of the present work, we investigated the role of channel and kinase 
domains of TRPM6 for the sensitivity of TRPM6/M7 channels to [Mg2+]i and [Mg·ATP]i. 
Because the functional consequences of the heterologous expression of human 
TRPM6 is surrounded by considerable controversy [68, 77, 92], we functionally 
characterized a newly cloned mouse TRPM6 cDNA. 
In the past, our laboratory extensively investigated the recombinant human TRPM6 
protein in HEK 293 cells, Xenopus oocytes and other expression systems [77]. It was 
found that human TRPM6 is retained in intracellular membrane compartments and that 
co-expression of TRPM6 and TRPM7 caused co-trafficking of TRPM6/M7 to the cell 
surface [77]. In addition, the interaction of TRPM6 with TRPM7 was shown by 
fluorescence resonance energy transfer (FRET) technique and co-immunoprecipitation 
approaches [77]. Currents mediated by TRPM6/M7 channels were higher than TRPM7 
currents [77]. 
However, it should be noted that other laboratories suggested that the recombinant 
human TRPM6 is able to function independently from TRPM7 [68, 92]. This idea was 
based on the observation that transient transfection of human TRPM6 in pCINeo-IRES-
GFP plasmid (but not other expression vectors) enables to induce TRPM6 currents 
without co-expression of TRPM7 [68, 92]. Of note, experiments with human TRPM6 in 
pCINeo-IRES-GFP vector produced different observations regarding the sensitivity of 
TRPM6 to intracellular levels of Mg2+ and [Mg·ATP]i. One laboratory demonstrated that 
TRPM6 is inhibited by [Mg2+]i and [Mg·ATP]i with IC50 of 510 µM and 1.3 mM, 
respectively [68, 100]. However, another group reported that human TRPM6 cDNA 
inserted in pCINeo-IRES-GFP allowed to elicit currents, which were insensitive to 3-9 
mM [Mg·ATP]i and highly sensitive to [Mg
2+]i with IC50 of 29 µM [92]. Mechanistically, 
these discrepancies remain to be explained. Specifically, it is unclear why only pCINeo-
IRES-hTRPM6-GFP plasmid enables to succeed a functional expression of TRPM6. 
Because the characteristics of human TRPM6 cDNA are rather controversial, in the 
present work we investigated a newly generated murine TRPM6 cDNA. We found that 
mouse TRPM6 cDNA could be functionally expressed irrespective of the vector 
backbone. Thus, an overexpression system did not completely recapitulated the 
characteristics of the native TRPM6 protein, since endogenous TRPM6 was active only 
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in the presence of TRPM7. Nevertheless, such experimental approach may be 
instrumental for dissecting functional impacts of the kinase versus channel activity of 
TRPM6 on regulatory features of the TRPM6/M7 channels. We observed that 
overexpression of mouse TRPM6 cDNA in HEK 293 cells allowed to detect TRPM6 
currents, which were substantially smaller than TRPM7 currents, suggesting that the 
formation of functional TRPM6 homomeric channels was considerably less efficient 
than TRPM7 channels. Furthermore, unlike TRPM7, TRPM6 currents were quickly 
inactivated. We also observed that, similar to TRPM7, TRPM6 is more permeable for 
Zn2+ as compared to Mg2+ and Ca2+. Most remarkably, the mouse TRPM6 channel was 
very sensitive to internal levels of Mg2+. TRPM6 was not active in the presence of 
nominally Mg2+ free buffer, indicating that TRPM6 homomers, if formed, will be blocked 
in the presence of physiological levels of Mg2+. We also found that the TRPM6 kinase 
is not involved in the extraordinary Mg2+ sensitivity of TRPM6. Our data show that, 
similarly to TRPM7 [110], TRPM6 activity is suppressed by the small organic molecule 
NS8593. Unlike TRPM7 [111], TRPM6 is complete insensitive to naltriben. In good 
agreement with [91], TRPM7 currents are inhibited by 2-APB, while TRPM6 currents 
are increased by this compound. Thus, the two channels exhibit a different response to 
pharmacological modulator. 
Next, we studied how TRPM6 alters the response of TRPM7 to [Mg2+]i and [Mg·ATP]i. 
We found that cells expressing TRPM6 and TRPM7 develop currents significantly 
bigger than cells transfected with only TRPM7, hence, recapitulating the situation in TS 
cells. TRPM6/M7 channels showed very high activity after break-in, indicating that 
these channels were active in the presence of cytosolic levels of Mg2+ and Mg·ATP. In 
line with this idea, we found that, unlike TRPM7, TRPM6/M7 currents were only 
modestly suppressed by physiological concentrations of Mg·ATP (3-9 mM) and were 
more active in the presence of physiological levels Mg2+ (0.5-1 mM). Finally, we 
observed that the TRPM6 kinase does not influence the low response of the 
TRPM6/M7 channels to internal Mg·ATP. 
To summarize, we found that TRPM6 and TRPM7 contribute differentially to key 
regulatory features of the TRPM6/M7 channels. Assembly of TRPM6 and TRPM7 
produce a new type of cation channel that is active in the presence of physiological 
levels of cytosolic Mg2+ and Mg·ATP. Accordingly, TRPM6/M7 channels will allow for a 
constant uptake of Mg2+ independent on the actual metabolic state of epithelial cells. In 
contrast, the TRPM7 channels are tightly controlled by [Mg2+]i and [Mg·ATP]i and, 
consequently, TRPM7 activity will be closely linked to cellular Mg2+ metabolism. This 
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model provides a plausible answer for the question as to why in transporting epithelia 
TRPM6 cannot be replaced by TRPM7. 
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6. Conclusions 
1. The native TRPM7 channel mediates Mg2+ and Mg·ATP sensitive divalent cation 
currents in TS, HAP1 and MKs cells. Genetic inactivation of TRPM7 in these cells 
leads to Mg2+ deficiency associated with a proliferation defect of TS and HAP1 
cells, indicating that TRPM7 channel is required for Mg2+ uptake into cells. 
 
2. In TS cells, the native TRPM6 protein functions primarily as a subunit of 
heteromeric TRPM6/M7 channel complexes. The association of TRPM6 with 
TRPM7 increases constitutive activity and reduces the sensitivity to cytosolic 
Mg·ATP of TRPM6/M7 channels. 
 
3. Recombinant mouse TRPM6 and TRPM7 overexpressed in HEK 293 cells 
recapitulate key characteristics of endogenous TRPM6 and TRPM7 channels. 
Specifically, recombinant mouse TRPM6 associates with TRPM7 to form 
heteromeric channel complexes, which remain active in the presence of 
physiological level of cytosolic Mg2+ and Mg·ATP. Such functional interplay of 
TRPM6 with TRPM7 may explain the nonredundant role of TRPM6 in Mg2+ 
transport by epithelial cell. 
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